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ABSTRACT 
 
Objective:  Body composition and energy homeostasis are thought to affect the 
appetitive hormones:  adiponectin, leptin, insulin, and ghrelin. This study examined 
whether centrally-located fat and/or overall adiposity were related to these appetitive 
hormones in healthy postmenopausal women. 
Design:  Overall and regional body composition was assessed by dual-energy X-ray 
absorptiometry in relation to plasma adiponectin, serum leptin, serum insulin, and 
plasma ghrelin in 242 postmenopausal women. 
Results:  Regression analyses revealed that the androidal-to-gynoidal fat mass ratio 
(18.0%), age (3.2%), and white blood cell count (1.8%) accounted for 28% of the 
variability in adiponectin (F=22.2; P<0.0001); androidal (waist + hip) fat mass (66.0%), 
(androidal fat mass)2 (6.2%), whole body lean mass (2.2%), and age (0.8%) accounted 
for 69% of the variability in leptin (F=102.5; P<0.0001). Regression analyses revealed 
that sagittal abdominal diameter (8.4%), glucose (5.4%), white blood cell count (2.6%), 
and dietary omega-3 fatty acids (2.0%) accounted for 32% of the variability in insulin 
(F=20.8; P<0.0001); waist circumference (12.7%), hip lean mass (2.0%), and white 
blood cell count (1.9%) accounted for 26% of the variability in ghrelin (F=20.7; 
P<0.0001). Our results indicated that centralized fat mass was the primary contributor to 
these appetitive hormones in healthy postmenopausal women. 
Conclusion:  Since central adiposity in postmenopausal women was related to 
appetitive hormones, minimizing weight gain during the menopausal transition may 
optimize appetitive hormones, thereby facilitating appetite control and weight 
maintenance. 
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GENERAL INTRODUCTION 
 
Thesis Organization 
 This thesis begins with a general introduction describing the objectives, 
hypotheses, specific aims, limitations, and significance of this research project. 
Objectives 
The first objective is to identify at baseline key biologic factors (particularly 
central adiposity and thigh lean mass) and nutritional status indices related to 
adiponectin, leptin, insulin, and ghrelin (Figure 1). The second objective is to determine 
whether adiponectin, leptin, insulin, and ghrelin change during the course of one year. 
The third objective is to determine whether soy isoflavones affect central adiposity or 
thigh lean mass, as mediated by adiponectin, leptin, insulin, and ghrelin. 
Hypotheses 
1. At baseline, central adiposity (androidal fat mass) will be positively related to serum 
leptin and insulin, but inversely related to plasma adiponectin and ghrelin, whereas 
lean mass in the thigh region will be positively related to adiponectin, but inversely 
related to leptin, insulin, and ghrelin in 242 healthy postmenopausal women. 
2. During the course of one year, we expect to document an increase in serum leptin 
and insulin, a decrease in plasma adiponectin, whereas no change in plasma ghrelin. 
Accordingly, we expect to document a gain in central adiposity, with a loss in thigh 
lean mass, among postmenopausal women who are not on active treatment. 
3. Long-term intake of soy isoflavone extract will ameliorate the menopause-related 
increase in central adiposity and loss of thigh lean mass in healthy postmenopausal 
women. 
a. Adiponectin, leptin, and insulin will mediate the effect of soy isoflavones on 
central adiposity, with leptin and insulin stimulating the increase and adiponectin 
inhibiting the increase in fat deposition. 
b. Appetitive hormones will mediate effect of soy isoflavones to beneficially 
influence body composition. 
Specific Aims 
1. To determine androidal fat (waist + hip) and gynoidal lean (thigh) mass at baseline 
using dual-energy x-ray absorptiometry (DXA) and relate central adiposity to 
adiponectin, leptin, insulin, and ghrelin concentration in postmenopausal women. 
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2. To determine the change in central adiposity and lean mass from baseline to one 
year in postmenopausal women with respect to treatment and relate these changes 
to adiponectin, leptin, insulin, and ghrelin. 
3. To examine the change, from baseline to one year, in central adiposity and thigh 
lean mass in postmenopausal women and determine whether change in body 
composition is influenced by soy isoflavone (80 or 120 mg/day) intake, as mediated 
by the hormones adiponectin, leptin, insulin, and/or ghrelin. 
Limitations 
The first limitation was that this ancillary cross-sectional study was hypothesis-
generating and thus could not determine cause and effect. In addition, the participants in 
this study were healthy postmenopausal women, primarily of Caucasian descent. Thus, 
our results cannot be generalized to all women across ethnic groups. The third limitation 
was that UC-Davis enrolled eight women with a BMI > 29.9 and one woman with a BMI 
<18.5, making the inclusion of protocol violators difficult to explain to reviewers. 
However, although these nine women did not meet our inclusion criteria, leading to 
greater variability in body weight, this may have allowed us to better examine the 
appetitive hormones in relation to central adiposity. The design of the overall Soy 
Isoflavones for Reducing Bone Loss (SIRBL) clinical trial was to determine the effect of 
two doses (80 and 120 μg) of soy isoflavones on bone, whereas this ancillary project 
examined the effect of isoflavones on central adiposity, taking adiponectin, leptin, insulin, 
and ghrelin into account. The fourth limitation of this study is that investigators will 
remain blinded until we have completed the intervention at both study sites in May 2008. 
Thus, the response-to-treatment statistical analyses will be completed this summer 
(2008) and this thesis does not include these analyses. Nevertheless, the manuscript in 
this thesis focuses on baseline data, irrespective of treatment. Thus, this thesis includes 
hypothesis and specific aim 1, but does not address the second and third hypotheses 
and specific aims, which will be the focus of a subsequent manuscript. 
Significance 
 Obesity increases the risk of atherosclerotic cardiovascular disease (CVD), 
insulin resistance, type 2 diabetes, hypertension, stroke, and cancer, all of which 
increase the risk of premature death. The appetitive hormones adiponectin, leptin, 
insulin, and ghrelin have all been studied as circulating hormones related to obesity. The 
most intensively studied hormones released from adipose tissue, the adipocytokines 
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such as adiponectin and leptin, are involved in mediating the amount and frequency of 
food consumed. Evidence suggests that dysregulation of adipocytokine production 
promotes the development of the metabolic and vascular diseases related to obesity 
(Funahashi et al. 1999). Further, hormones produced by the stomach and pancreas, 
ghrelin and insulin, respectively, play a significant role in energy homeostasis. 
As women transition through menopause they experience a rapid decline in 
ovarian function and a subsequent decline in circulating reproductive hormones, 
including estrogen. Menopause-induced hormonal changes result in an increase in 
overall adiposity (Tchernof et al. 2004), but especially visceral adiposity (Lovejoy et al. 
2008). Postmenopausal women may experience an increase in adiposity in the central 
region that translates into a greater risk of obesity and subsequent chronic disease. 
Hormone therapy (HT) has been prescribed as a method to decrease women’s risk for 
chronic disease; however, the Women’s Health Initiative Trial demonstrated that HT may 
carry greater risks than benefits (Rossouw et al. 2002). Since this trial, HT use has 
declined (Ettinger et al. 2003) and women are searching for alternative therapies to 
relieve menopausal symptoms. Soy isoflavones, with their estrogen-like properties, are 
thought by some to be an ideal alternative to HT because of perceived health benefits 
(Messina 2002). However, we have sparse information on the effect of soy isoflavones 
on body composition in humans. Further, research on the effect of soy isoflavones on 
adiponectin, leptin, insulin, and ghrelin in postmenopausal women is limited and 
inconsistent. As this manuscript explains, central adiposity in postmenopausal women 
was related to appetitive hormones, despite the apparent health of the women enrolled 
in the study. Thus, minimizing weight gain during the menopausal transition may 
optimize appetitive hormones, thereby facilitating appetite control and weight 
maintenance. 
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Figure 1:  Study design:  Conceptual framework 
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REVIEW OF LITERATURE 
 
OVERVIEW OF OBESITY 
The prevalence of obesity in the United States (U.S.) has markedly increased in 
the past 25 years and needs urgent attention. Approximately 65% of U.S. adults are 
overweight or obese (Hedley et al. 2004). Obesity increases the risk of atherosclerotic 
CVD, insulin resistance, type 2 diabetes, hypertension, stroke, and cancer, all of which 
increase the risk of premature death. In 2000, approximately 365,000 deaths in the U.S. 
were associated with obesity (Mokdad et al. 2005). Further, the economic cost was more 
than $117 billion, with annual medical expenditures 36% higher for obese versus non-
obese individuals (Sturm 2002). This disease is influenced by a variety of factors such 
as genetics, environment, socioeconomic status, and behavior (Rashid et al. 2003). One 
analogy for this chronic multifactorial disease is that genetics loads the gun but a 
permissive or toxic environment pulls the trigger (Bray & Champagne 2005). Obesity is 
attributed in part to the American lifestyle:  physical inactivity, high consumption of 
energy-dense foods, large portion sizes, sleep deprivation, and continual high levels of 
stress related to fast-paced lifestyles. Currently, for most overweight individuals, there 
are no proven, effective approaches for meaningful and long-term weight loss (Hill & 
Peters 1998). 
Definitions:  Overall Adiposity, Androidal versus Gynoidal Adiposity 
Obesity is a general term used to describe the overall accumulation of body fat. 
Overall adiposity is adipose tissue accumulated throughout the whole body 
(subcutaneously and internally), whereas regional fat distribution is the location of 
adipose tissue in specific regions, yet being very different across the life cycle, as well as 
between the sexes and among ethnic groups (Malina 1996). The location of body fat is 
critical in terms of risk of chronic disease, with central adiposity conferring greater health 
consequences. Typically, researchers classify individuals into two body types:  those 
with either an androidal (“apple”) or a gynoidal (“pear”) shape. Androidal adiposity is 
characterized by adipose tissue deposited in the abdominal (trunkal or central) region, 
whereas gynoidal adiposity is characterized by adipose tissue deposited in the 
gluteofemoral (thigh) region (Malina 1996). The size of adipocytes varies, depending 
upon the weight and adiposity of the individual and upon the site of storage. For 
example, Garaulet et al. (2000) studied adipocytes of obese women undergoing 
abdominal surgery or laparoscopy and found those women with a gynoidal shape 
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possessed significantly smaller and more numerous adipocytes than women with an 
androidal shape. 
The terms fat and adipose tissue are used interchangeably; however, they have 
different meanings in the scientific community. Fat is a chemical component of the food 
system and is found in body compartments, such as adipose and muscle tissue, in the 
form of lipid or triacylglycerol (TAG). Adipose tissue is defined as specialized loose 
connective tissue composed of adipocytes (Shen et al. 2003). About 80% of adipose 
tissue is lipid, with the remaining 20% composed of water, protein, and minerals (Snyder 
et al. 1975). Adipose tissue is actively involved in energy storage of lipid, thermal 
insulation, provides a protective padding/cushioning around internal organs, and is an 
important endocrine organ that functions in the regulation of food intake. 
Implications for Disease Risk 
These two body shapes or types (androidal versus gynoidal) confer health 
implications for disease risk. Those individuals with androidal adiposity are at an 
increased risk of chronic diseases/conditions such as dyslipidemia, hypertension, 
atherosclerotic CVD, and diabetes. The reason for the difference between these two 
body types in disease risk is currently unknown, but it is thought to be related to the 
different types of adipose tissue. Further, visceral adipose tissue is more likely to release 
free fatty acids into the circulation because it is more sensitive to lipolytic stimuli (Snijder 
et al. 2006). However, other research suggests that these findings are inconsistent 
(Tchernof et al. 2006). This group studied healthy women and found that on an absolute 
basis, subcutaneous adipocytes located in the abdominal region are larger, have higher 
lipolysis rates per cell, and higher lipoprotein lipase activity compared with omental 
(deep visceral) adipose tissue. They suggested that larger subcutaneous adipocytes 
accumulate greater TAG and also release greater fatty acids than smaller adipocytes. 
Regardless, the released free fatty acids enter directly into the portal vein. Excess 
energy may be stored in the intra-abdominal adipose tissue, visceral organs (such as the 
liver), and/or skeletal muscle. However, excess fatty acids stored in the liver and skeletal 
muscle have metabolic consequences distinct from that of subcutaneous fat. Increased 
fatty acid storage in the liver causes dyslipidemia and hepatic insulin resistance 
(Seppala-Lindroos et al. 2002). Increased fatty acid storage in the skeletal muscle is 
associated with skeletal muscle insulin resistance (Sinha et al. 2002). 
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In contrast, gynoidal adiposity does not increase disease risk in the same 
manner as androidal obesity. In fact, some researchers consider gynoidal adiposity as 
protective against disease (Snijder et al. 2005), possibly due to the larger amount of 
muscle mass located in the thigh region or to the relatively large proportion of 
subcutaneous compared with internal fat located in the gluteofemoral (thigh) region. 
Also, it has been suggested that the thigh subcutaneous fat acts as a “metabolic sink” for 
circulating free fatty acids (Frayn 2002). Lipolytic activity in the thigh subcutaneous fat is 
different from that of abdominal subcutaneous fat due to high lipoprotein lipase activity in 
this region (Rebuffe-Scrive et al. 1985), especially in women. Thus, thigh subcutaneous 
fat is more likely to take up free fatty acids from and less likely to release free fatty acids 
to the circulation (Snijder et al. 2006). Further, Bos et al. (2005) found that for women, 
larger thigh fat mass was associated with higher lipoprotein lipase activity. Recent 
evidence supports this hypothesis by comparing lower and upper body subcutaneous 
adipose tissue in women. The women with greater adiposity, as assessed by DXA, 
stored greater free fatty acid in the lower body subcutaneous adipocytes versus the 
upper body subcutaneous or visceral adipocytes, as reflected by a free fatty acid tracer 
(Koutsari et al. 2008). Thus, the gynoidal body shape may protect other organs from 
ectopic fat exposure and accumulation, leading to a lower risk of insulin resistance. 
Adipose Tissue Compartments 
 Subcutaneous and intra-abdominal adipose tissue 
Adipose tissue is compartmentalized into specific regional depots, with each 
compartment serving as a storage location that carries specific disease risk. Adipose 
tissue storage is divided into two compartments, subcutaneous adipose tissue (fat 
accumulated under the skin) and intra-abdominal adipose tissue (visceral or fat 
accumulated around the organs). The literature is vague in describing these two 
compartments because they are much more complex than one might initially think. Shen 
et al. (2003) identified specific sub-compartments of subcutaneous and intra-abdominal 
(visceral) adipose tissue storage (Table 1). In the lower trunk and gluteal-thigh region, 
subcutaneous adipose tissue is divided by the fascial plane into superficial and deep 
subcutaneous adipose tissue (Figure 2). Superficial subcutaneous adipose tissue is the 
layer between the skin and the fascial plane in the gluteal-thigh area, whereas the deep 
subcutaneous adipose tissue layer is found between the muscle fascia and the fascial 
plane in the gluteal-thigh area. The deep subcutaneous adipose tissue is located in the 
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posterior half of the abdomen, whereas the superficial subcutaneous adipose tissue is 
evenly distributed around the abdomen. Shen et al. (2003) classify the intra-abdominal 
adipose tissue as internal adipose tissue, which is the total body adipose tissue minus 
the subcutaneous adipose tissue. Internal adipose tissue is further divided into visceral, 
or the adipose tissue within the chest, abdomen, and pelvis; and nonvisceral, the internal 
adipose tissue minus visceral adipose tissue. The visceral adipose tissue compartment 
is further divided into intra-thoracic and intra-abdominopelvic. Within these 
compartments are sub-compartments:  intra-pericardial (e.g., omental and mesenteric) 
and extra-pericardial, as well as intra-peritoneal and extra-peritoneal adipose tissue. 
 
Adipose Tissue Compartment 
Subcutaneous adipose tissue 
    Superficial subcutaneous adipose tissue 
    Deep subcutaneous adipose tissue 
Internal adipose tissue 
    Visceral adipose tissue 
        Intrathoracic adipose tissue 
            Intrapericardial 
            Extrapericardial 
        Intraabominopelvic 
            Intraperitoneal 
            Extraperitoneal 
Table 1:  Proposed classification of adipose tissue (Adapted from Shen et al. 2003) 
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Figure 2:  Abdominal axial computed tomography scan. White arrows indicate 
location of subcutaneous adipose tissue division into superficial and deep subcutaneous 
adipose tissue by a fascial plane. 
 
Lean Tissue 
The largest component of the body is lean tissue, comprised of skeletal muscle, 
smooth muscle, and bone. Lean tissue mass, according to Roche (1996), is the whole 
body minus the adipose tissue that is visible to the eye. Muscle, especially skeletal 
muscle, plays an important role in body weight homeostasis. Typically when we consider 
skeletal muscle, we think about its role in strength, but it also plays a major role in 
carbohydrate and lipid storage. Skeletal muscle is the major site for insulin-stimulated 
glucose disposal (DeFronzo et al. 1981). Lipid droplets, stored as TAG, accumulate 
within skeletal muscle and have been shown to be positively related to insulin resistance 
in European and South Asian men (Forouhi et al. 1999). Skeletal muscle, the largest 
component of lean tissue, is primarily located in the legs, with lesser amounts in the 
trunk, arms, and head (Lukaski 1996). Although lean tissue is typically not considered in 
obesity, it is important to assess because it is metabolically active, storing and releasing 
compounds related to metabolism. However, research relating lean tissue to obesity is 
A. Obese Subject
B. Thin Subject
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limited. It is difficult to measure lean tissue because it is located internally, yet 
surrounded by adipose tissue. Further, increased lean mass and muscle strength, 
particularly localized in the legs, has been associated with higher fat mass (Lebrun et al. 
2006). This finding is most likely due to the greater overall mass that must be supported 
by the legs. 
Lean tissue is commonly assessed by anthropometric measures, muscle 
metabolites, and/or radiologic measures. Although anthropometry is more commonly 
used to assess fat mass, lean mass may be assessed using circumference 
measurements of the arms or legs. Two of the most common muscle metabolites to 
assess lean mass are creatinine and 3-methylhistidine (Ballard & Tomas 1983). 
However, muscle metabolites are not commonly used because they require a 24-hour 
urine collection and 3-methylhistidine is technically difficult to accurately measure. 
Radiologic measures, such as computed tomography or DXA, are the most useful 
methods to assess lean tissue because they provide a direct visualization of body 
composition. However, radiation exposure may be a concern with these methods, 
particularly because computed tomography requires high doses of radiation. In addition, 
this method is most valuable to assess centrally-located fat, rather than whole body lean 
mass. 
Methodology to Assess Regional Fat and Lean Tissue Distribution 
Overall obesity may be assessed by calculating body mass index (BMI), but this 
is very crude. There are many anthropometric measures used to assess body fat 
distribution, particularly centrally-located fat, such as waist, abdominal, and hip 
circumferences; waist-to-hip ratio (WHR); sagittal abdominal diameter; and skinfold 
thickness (subscapular, waist, abdomen). Researchers debate about which method to 
use under what circumstances, since not all methods reflect internal fat, the 
metabolically active fat that is closely related to disease risk. Inconsistency among 
studies about which method is the most precise, reliable, and sensitive to change may 
be due to differences in sample characteristics and in measurement methods. 
Anthropometric measurements 
Body mass index:  A commonly used but crude measure to assess relative 
weight is BMI (kg/m2), allowing a consistent classification system across study samples. 
The World Health Organization (WHO) (2004) classified individuals within the following 
BMI ranges:  18.5 to 24.9 kg/m2 – normal or lean; 25.0 to 29.9 kg/m2 – overweight; >29.9 
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kg/m2  – obese. Research has demonstrated a direct relation between BMI and risk of 
diabetes (Colditz et al. 1995). Individuals with a BMI of 25 or greater are at a higher risk 
for obesity-related adverse health outcomes than those with a BMI less than 25. 
Although BMI is widely used, there are many limitations to using BMI as a tool to 
quantify obesity or adiposity. Some individuals carry a disproportionate amount of lean 
mass, such as football players, and consequently may be considered overweight or 
obese if based on BMI when in fact their percent body fat may be quite low. Also, BMI 
may not be a good indicator of obesity across the races (Evans et al. 2006), since it has 
been shown to inaccurately indicate obesity in black but not white women. Although the 
black women had a higher (p < 0.05) BMI than the white women, percent body fat 
(based on DXA) was not different. These researchers also found that the BMI cut-off of 
30 kg/m2 was too high to accurately classify obese versus nonobese black and white 
postmenopausal women. Further, the BMI cut-point for obesity that was equivalent to 38 
percent body fat (recommended by Lohman et al. 1997 for middle-aged woman) was 
different in black versus white women. Lastly, BMI does not accurately estimate 
abdominal fat, which correlates most closely with chronic disease risk. Many studies 
indicate that it is more critical to assess abdominal fat than overall adiposity in assessing 
chronic disease risk. 
Body circumferences (waist, hip, thigh):  Waist circumference is an 
anthropometric girth measure around the smallest part of the waist, typically taken to 
accurately assess abdominal adiposity. Men and women are at an increased 
cardiometabolic risk with a waist circumference greater than 102 cm (40 inches) and 88 
cm (35 inches), respectively. Recently, a consensus statement has been published from 
a number of health-related organizations (Shaping America’s Health:  Association for 
Weight Management and Obesity Prevention; North American Association for the Study 
of Obesity, The Obesity Society; The American Society for Nutrition; The American 
Diabetes Association), suggesting that waist circumference be adopted as the best 
method of assessing adiposity in a clinical setting. This panel, organized by the National 
Heart, Lung, and Blood Institute, recommended using waist circumference because, 
when compared with BMI, it better predicts intra-abdominal adipose tissue (Klein et al. 
2007). Since increased adiposity is associated with elevated CVD risk, the expert panel 
suggested using waist circumference as a clinical tool to assess the risk of developing 
elevated blood pressure, dyslipidemia, and hyperglycemia. Studies support the idea that 
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waist circumference is a key predictor of diabetes, CVD, and mortality, independent of 
blood pressure, glucose concentration, and lipoproteins (Yusuf et al. 2005; Wang et al. 
2005). Although waist circumference cannot quantify the amount of abdominal adipose 
tissue, it is a useful method to assess abdominal adiposity and hence cardiometabolic 
risk. Interestingly, Wang et al. (2005) have also found that waist circumference was a 
better measure than BMI or WHR in predicting type 2 diabetes among 27,270 men. In 
fact, Moreira et al. (2007) found that waist circumference was a better measure than BMI 
or WHR for obese women to assess the prevalence of mood disorders and depressive 
symptoms. Although this assessment method is relatively easy, a definitive standard 
procedure for measurement is still needed because researchers define “waist” 
differently. Parikh et al. (2007) suggested that height be taken into consideration when 
measuring waist circumference to assess central adiposity. Their rationale is because 
individuals within the same group who have identical waist circumference 
measurements, but different heights, have dissimilar risk for chronic disease. These 
researchers define an index of central obesity as the ratio of waist circumference and 
height and suggest that in the U.S., the index of central obesity cutoff for men and 
women should be 0.58 and 0.54, respectively. 
Another commonly used anthropometric index to assess body fat distribution is a 
combination of waist and hip circumferences expressed as WHR, with hip measured 
around the widest girth. The WHR is calculated using the waist circumference divided by 
the hip circumference. Both WHR and waist circumference are related to visceral 
adipose tissue; however, waist circumference is more strongly associated with visceral 
adipose tissue (Pouliot et al. 1994; Onat et al. 2004). Lemieux et al. (1996) suggested 
that a WHR of 0.94 for men and 0.88 for women relate to an accumulation of adipose 
tissue. However, recent research has determined that the 0.88 cut-off does not 
accurately predict CVD risk for pre- and postmenopausal women alike. Azizi et al. (2005) 
found that a WHR of > 0.78 for premenopausal and > 0.84 for postmenopausal women 
more accurately assesses the risk of CVD because of the increase in fat mass after 
menopause. However, more recent research, contrary to reports from the 1990s and 
earlier, has suggested that WHR is not an adequate measure to assess body fat 
distribution. In fact, the American Heart Association no longer recommends using this 
index to assess adiposity, stating that this method is not as suitable as BMI or waist 
circumference (americanheart.org, 2007). According to Gambacciani et al. (1997), the 
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WHR method may underestimate abdominal fat in obese individuals. Nevertheless, 
some researchers (Seidell et al. 2001; Okura et al. 2004; Heitmann et al. 2004) have 
found that WHR is inversely related to dyslipidemia, diabetes, hypertension, CVD, and 
death, suggesting that it relates more closely with central adiposity than overall. 
However, the WHR, because it includes the hip circumference, typically measured at the 
widest girth at the point of the greater trochanter, reflects muscle and fat mass but does 
not include the abdominal region. Hip circumference is a combination of fat and lean 
mass and thus is associated with subcutaneous fat, gluteal muscle, and total leg muscle 
mass (Seidell et al. 2001). Thus, the purported cardioprotective association of hip 
circumference may be related to the muscle mass that is included in this measurement. 
According to a meta-regression analysis of 15 prospective studies, a 0.01 increase in 
WHR was associated with a 5% increase in CVD risk (de Koning et al. 2007). 
Thigh circumference is not as commonly assessed as waist or hip circumference. 
Thigh circumference is an indicator of both muscle and subcutaneous adipose tissue 
and is measured around one thigh, typically at the mid-thigh between the inguinal crease 
and the proximal border of the patella (Snijder et al. 2005). Snijder et al. (2003) found 
that both the waist-to-thigh circumference ratio and WHR were better predictors of type 2 
diabetes risk than either waist circumference or BMI alone in a prospective study of 1357 
(619 men and 738 women) French Canadian subjects. In fact, a larger thigh 
circumference was associated with a lower risk of diabetes, although this protective 
effect was only statistically significant in women. Another study by Snijder et al. (2005) 
called the Health, Aging, and Body Composition Study (Health ABC Study) found that 
high subcutaneous thigh fat was independently associated with more favorable glucose 
and lipid concentrations. Van Pelt et al. (2005) found that thigh fat mass was associated 
with a reduced risk of CVD, supporting the idea that a gynoidal body shape is 
considered protective against disease risk. This may be because the storage of fat is 
subcutaneous, away from the organs, instead of storage in the visceral region. 
Sagittal abdominal diameter:  Another method to assess abdominal adiposity is 
sagittal abdominal diameter that is taken in the supine position with knees bent using a 
portable, sliding-beam, abdominal caliper. It measures the anterior to posterior tissue 
thickness of the abdomen, midway between the iliac crests at the L4-L5 level (Kahn et 
al. 1996). Researchers (Riserus et al. 2004; Petersson et al. 2007) have shown that 
sagittal abdominal diameter better reflects obesity-related metabolic disturbances such 
  
14
as CVD and inflammation than BMI, waist circumference, or WHR. Sagittal abdominal 
diameter is probably an excellent indicator of CVD risk because it is strongly associated 
with visceral fat (Zamboni et al. 1998), because abdominal subcutaneous fat shifts to the 
sides of the waist as the measurement is taken in the supine position (Mukuddem-
Petersen et al. 2006). These researchers found that in an elderly sample, sagittal 
abdominal diameter was not more advantageous than BMI, waist circumference, or 
WHR measurements. Although this method of assessing abdominal adiposity needs 
further research to determine its validity across various subject samples, it holds promise 
because it has very high inter- and intra-observer precision (Zamboni et al. 1998) and 
does not require radiation or sophisticated equipment. 
 Radiographic measurements 
Quantitative computed tomography; dual-energy x-ray absorptiometry:  Currently, 
there are two main radiographic techniques for assessing regional fat and lean tissue 
distribution, computed tomography and DXA. The most accurate indirect method for 
assessing abdominal adipose tissue, particularly visceral adipose tissue, is computed 
tomography (Despres et al. 1996). This method is considered the reference “gold 
standard”, but use of this machine for research is limited because of expense, access to 
the scanner, and exposure of subjects to significant amounts of radiation (Plourde 1997). 
Thus, DXA is more commonly used in clinical practice because it provides a reliable 
estimate of body composition with minimal radiation exposure (Park et al. 2002). The 
DXA instrument is typically used to assess hard tissue (bone); however, DXA can also 
be used to assess soft tissue (lean and fat tissue). Although computed tomography is 
considered the gold standard, DXA has been shown to provide accurate and reliable 
estimates of overall body composition (Glickman et al. 2004). However, DXA cannot 
differentiate between subcutaneous and visceral adipose tissue because measurements 
are only two-dimensional. Although these fat depots cannot be determined directly using 
DXA, the soft tissue from the DXA scans are often used to estimate visceral adipose 
tissue by dividing the whole body scan into regions (Snijder et al. 2002). In addition, the 
investigator can partition DXA scans into particular regions of interest that relate 
significantly to visceral fat (Park et al. 2002; Glickman et al. 2004). Park et al. (2002) 
compared four centralized regions of interest from DXA scans:  1) the upper edge of the 
second lumbar vertebra to the lower edge of the fourth lumbar vertebra; 2) the upper 
edge of the second lumbar vertebra to above the iliac crest; 3) the lower costal margin to 
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above the iliac crest; and 4) the region of interest 3 excluding the spine. They found that 
the fat tissue was related to total visceral adipose tissue and was similar to an actual 
measure of visceral adipose tissue from magnetic resonance imaging. Glickman et al. 
(2004) compared DXA and computed tomography scans, defining the abdominal region 
as fat mass located between the first and fourth lumbar vertebrae (L1 and L4). According 
to this research group, DXA provided a valid method to determine abdominal adiposity in 
comparison with computed tomography and performed as well as computed tomography 
with respect to reproducibility. 
 
RELATIONSHIP OF OBESITY WITH KEY FACTORS 
Physical Activity 
Studies are underway to assess the current activity profiles and level of physical 
activity among Americans. However, researchers debate about how to best assess 
physical activity such that energy expenditure is accurately captured. It is difficult to 
assess physical activity because it is a complex, multidimensional behavior (Wareham 
2007). For example, individuals participate, consciously or unconsciously, in a variety of 
physical activities throughout the day, including activities of daily living at home, 
occupation-related activities, physical activity related to transport, and recreational 
exercise. Thus, assessing physical activity in free-living situations is difficult and hence 
researchers most often rely upon self-reported data. Physical activity assessment needs 
to consider the type of activity, intensity, frequency, and duration to accurately estimate 
total energy expenditure. 
Regular physical activity, fitness, and exercise are critically important for the 
health and well being of individuals across the life cycle. The Department of Health and 
Human Services and United States Department of Agriculture jointly released in 2005 
new Dietary Guidelines for Americans (http://www.healthierus.gov/dietaryguidelines). In 
addition to the dietary recommendations, these guidelines also recommended exercise 
to encourage Americans to participate in an active lifestyle. These experts suggested 
engaging in at least 30 minutes of moderate intensity physical activity on most days of 
the week for weight maintenance and 60 minutes of moderate intensity activity on most 
days to sustain weight loss. Incorporating physical activity into everyday life has well-
recognized health benefits. According to the Surgeon General’s Report on Physical 
Activity and Health (1996), the benefits of physical activity include:  lowered mortality, 
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decreased risk of CVD and some cancers, enhanced insulin sensitivity and subsequent 
reduced risk of developing type 2 diabetes, reduced risk of osteoporosis, greater muscle 
mass, and lesser fat mass, thus lowering the risk of associated comorbidities. However, 
the prevalence of obesity in the U.S. continues to rise, which simultaneously has 
coincided with decreased levels of physical activity. Research has also shown that 
increasing physical activity is a key element in treating obesity and in preventing weight 
regain in those who have successfully lost weight (Wareham 2007). Further, low levels 
of physical activity are associated with a high risk of CVD and mortality (Blair et al. 1989; 
Talbot et al. 2007). The prevalence of physical inactivity progressively increases with 
age (Talbot et al. 2007); approximately 30% of postmenopausal women report that they 
do not engage in physical activity (Centers for Disease Control 2005). In fact, during the 
postmenopausal years, fitness levels decline 1 to 2% per year (Fleg et al. 2005). 
People who exercise typically have less abdominal fat than those who do not 
exercise (Lofgren et al. 2004). In fact, this study found that those individuals with a 
smaller waist circumference recorded more daily steps (as captured by pedometers) 
than those with a larger waist circumference. Similarly, Ross et al. (2003) found that 
subjects with higher levels of cardiorespiratory fitness had a lower risk of developing 
chronic diseases due to less abdominal fat. Further, exercise in women may affect 
various adipose tissue stores differently than in men. Women who exercise have 
markedly increased lipolysis in abdominal compared with femoral (thigh) subcutaneous 
adipose tissue (Horowitz et al. 2000). This suggests that exercise-induced weight loss 
would be associated with a preferential reduction in abdominal adiposity, although this 
was not tested directly. In a study of premenopausal obese women, substantial 
reductions in abdominal (10%) and visceral (18%) fat were noted in the women who 
exercised but who did not lose weight (Ross et al. 2004) compared with women who 
attempted only dietary-induced weight loss. Physical activity may also reduce appetite 
and fat intake (Saris 1999), thus reducing the amount of energy consumed. These 
studies combined illustrate the importance of exercise and cardiorespiratory fitness in 
weight loss and weight maintenance. However, substantial energy deficit through 
exercise alone is very difficult to achieve, demonstrating the importance of the 
combination of exercise and dietary change. 
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Dietary Intake 
 Although genetics play a role in weight gain, it cannot independently explain the 
dramatic increase in the development of obesity during the past several decades. In the 
U.S., diets high in fat and energy have paralleled the increase in the prevalence of 
obesity as an epidemic. The consumption of food involves many aspects of life, including 
social, cultural, and economic factors that determine food intake behavior. The prevailing 
thought is that the typical Western diet promotes excess energy intake and a positive 
energy balance, with an average of 37-42% of energy derived from fat (Uauy & Diaz 
2005). Nutritional epidemiologic research typically assesses single nutrients to examine 
association with disease risk; however, this approach may not account for nutrient 
interactions in vivo. More recently, a dietary pattern approach has been studied, which 
uses cluster analysis to examine the effect of overall diet on disease risk, thereby 
allowing more conclusive results related to diet and disease (Newby & Tucker 2004; 
Okubo et al. 2007). 
Energy 
Obesity is often caused by excess energy intake over time (McCrory et al. 2000) 
relative to energy expenditure. Typical meals in the U.S. promote positive energy 
balance because of large portion sizes, consumption of energy dense convenience 
foods, lack of nutrient dense foods, and eating away from home, all of which contribute 
to our obesity epidemic. Per capita energy intake in the U.S. food supply has increased 
steadily in the past 40 years, as demonstrated by the figure below (Gerrior et al. 2004). 
According to the Nutrient Content of the U.S. Food Supply (1909-2000) report from the 
Home Economics Research Report No. 56 by the U.S. Department of Agriculture 
(USDA), ~3,100 kcal/day were consumed in 1965, whereas more recently (2000), 
energy intake has risen to ~3,900 kcal/day, based upon the available food supply. 
Further, data from the Centers for Disease Control & Prevention (CDC 2004) indicated 
that, between 1971 and 2000, men and women reported a combined increase in daily 
energy intake of 168 and 335 kcal, respectively, based upon actual estimated intake. 
An increase in daily energy intake can translate into weight gain and increase the 
risk for disease. Findings from Howarth et al. (2006) suggest that an energy dense diet 
is a risk factor for elevated BMI in both men and women across ethnic groups. According 
to Howarth et al. (2007), total and snack and mealtime energy intake was positively 
associated with BMI in both younger (average = 38.5 years) and older (average = 71.0 
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years) adults. Although overweight/obese adults and their normal weight counterparts do 
not necessarily differ significantly in the amount of energy consumed, they do differ in 
the composition of their diet derived from fat and carbohydrate (Davis et al. 2006), 
suggesting that diet composition plays a vital role in promoting or preventing obesity. 
However, the role of diet composition in weight control and obesity remains 
controversial. 
 
Figure 3:  Daily per capita food energy in the U.S. food supply (1909-2000) 
 
Carbohydrate 
In 2004, the CDC reported that since 1970, Americans have increased their 
carbohydrate consumption by 60-70 g/day. Carbohydrate quality and quantity has been 
the subject of discussion among researchers for many years. Current recommendations 
emphasize the intake of complex, fiber-rich carbohydrate with a low glycemic index, 
whereas high-glycemic refined carbohydrate foods should be limited (USDA 2007). 
Gross et al. (2004) suggested that diets with a high glycemic index (glycemic load) 
increase the risk of obesity and its associated health problems. In a study of 63,307 
postmenopausal women aged 50-74 years enrolled in the Cancer Prevention Study II 
Nutrition Cohort (Jonas et al. 2003), a higher intake of carbohydrate was associated with 
a lower risk of obesity and had an inverse relationship with BMI. Further, in a study of 
age- and height-matched normal and overweight/obese adults, the overweight/obese 
adults consumed a smaller proportion of their energy from carbohydrate, specifically 
complex carbohydrate and dietary fiber, than their normal weight counterparts (Davis et 
al. 2006). The overweight/obese adults consumed more simple sugars than the normal 
weight adults. Simple sugar intake is high among those living in the U.S., in part 
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because high-fructose corn syrup and other sweeteners are used in place of sucrose in 
many foods and most sweetened beverages. Coincidently, consumption of high-fructose 
corn syrup has increased in parallel with the rise in obesity. In fact, Bray & Champagne 
(2005) suggested that the high prevalence of obesity is due to the consumption of high-
fructose corn syrup. However, others have suggested that the relationship between high-
fructose corn syrup and elevated body weight is very weak (Forshee et al. 2007). 
Fiber 
The inverse relationship between carbohydrate consumption and BMI may partly 
be due to the fiber content of carbohydrate (Schulze et al. 2004). Dietary fiber may 
facilitate weight reduction because high fiber foods are typically nutrient dense, low in fat 
and/or energy content, and may displace energy dense foods, thus decreasing overall 
energy intake. Hence, a low fiber intake may, among other factors,  contribute to excess 
energy intake. Dietary fiber slows gastric emptying, decreases the absorption of energy-
yielding nutrients, and enhances satiety (Baer et al. 1997; Uauy & Diaz 2005), potentially 
decreasing energy intake. Dietary fiber may also decrease the risk of obesity because of 
its physical characteristics, such as its high viscosity, great water-holding capacity, and 
hence potential to increase the bulk/volume of stools. Women 20-59 years of age with a 
high dietary fiber intake, particularly in the context of a low fat intake, had a lower BMI 
than women with a low fiber intake (Howarth et al. 2005). Further, dietary fiber 
(assessed by a self-administered food frequency questionnaire) has been shown to be 
inversely related to diabetes risk in a prospective cohort study of 35,988 older women 
(Meyer et al. 2000) with insulin resistance (using the homeostasis model assessment of 
insulin resistance; HOMA-IR) in a cross-sectional study of 5,675 subjects aged 30-60 
years (Lau et al. 2005). Many individuals in the U.S. do not consume the recommended 
20-25 g/day of fiber, but research clearly suggests the benefits of dietary fiber intake. 
Total fat 
 The total amount of fat is of concern in the U.S. diet because a diet high in fat, 
even in the absence of energy excess, has been shown to contribute to the obesity 
epidemic (Bray & Popkin 1998; Satia-Abouta et al. 2002). For examples, in a study of 
age- and height-matched overweight/obese versus normal weight adults, the 
overweight/obese individuals consumed a larger portion of their energy from fat (Davis et 
al. 2006). A longitudinal study of 14 years duration, with 782 Hispanic and non-Hispanic 
adults, found that dietary fat (independent of total energy intake) was positively 
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associated with weight gain and that high intake of dietary fat was strongly related to 
weight gain (Mosca et al. 2004). They also found that individuals with relative insulin 
resistance (measured by quantitative insulin sensitivity check index) at baseline, who 
also had a high dietary fat intake gained the greatest amount of weight. Dietary fat and 
its role in obesity is debatable because research supports that individuals who have 
attempted a low carbohydrate, high fat and/or high protein diet lost weight (Westman et 
al. 2002). Some health professionals suggest that it is the type of dietary fat that impacts 
health, although this remains controversial. 
Type of fat:  Fats are derived from animal and plant sources and are comprised 
of a variety of fatty acids. The degree of fatty acid saturation and the presence of double 
bonds have different implications for disease risk. Dietary saturated and trans fatty acids 
exert the most harmful effects because they tend to raise low density lipoprotein (LDL) 
cholesterol (Mensink & Katan 1992; Willet et al. 1993), thus increasing the risk of 
atherosclerosis (Hu et al. 1997). Interestingly, a low saturated fatty acid intake in men 
and women enrolled in the Framingham Offspring Study was significantly associated 
with smaller LDL particles (Campos et al. 1992), suggesting that a low saturated fatty 
acid intake confers greater atherosclerotic risk. However, saturated fatty acids are not as 
readily oxidized as unsaturated fatty acids (Gaster et al. 2005). Nevertheless, according 
to Rivellese et al. (2003), a high saturated fatty acid intake negatively influenced the 
cholesterol and TAG content of the LDL particle in 162 healthy Caucasian men and 
women. Increased saturated fatty acid intake has also been related to the development 
of insulin resistance in humans (Maron et al. 1991). One cross-sectional study found that 
fasting serum insulin concentration was positively associated with the percentage of 
saturated fatty acids in plasma phospholipids and inversely associated with the 
percentage of monounsaturated fatty acids (MUFA) in plasma phospholipids (Folsom et 
al. 1996). Thus, decreasing dietary saturated fatty acids may result in a reduced risk of 
insulin resistance. Trans fatty acids are also of public health concern because they raise 
the risk of type 2 diabetes (Salmeron et al. 2001). Some suggest that trans fatty acids 
decrease insulin sensitivity (Christiansen et al. 1997); however, Lovejoy et al. (2002) 
found that trans fatty acids did not have any effect on insulin sensitivity or secretion. 
Unsaturated, or MUFA and polyunsaturated (PUFA) fatty acids, improve the 
lipoprotein profile (Binkoski et al. 2005), particularly if they partially replace saturated 
fatty acids. Replacing saturated fatty acids with PUFA has been shown to decrease LDL 
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cholesterol to a greater extent than MUFA (Mensink & Katan 1992). However, diets high 
in MUFA in comparison with PUFA have been shown to reduce the susceptibility of LDL 
to oxidative modification during the development of atherosclerosis (Bonanome et al. 
1992). In healthy men and women, Rivellese et al. (2003) found that high MUFA diets 
had beneficial effects on LDL cholesterol and TAG. However, the high MUFA diet also 
increased lipoprotein (a) (Lp(a)), another marker of CVD risk. They suggested that this 
increase was insignificant, considering the other beneficial effects of a high MUFA diet. 
Rasmussen et al. (2006) found that a MUFA-rich diet, unlike a saturated fatty acid-rich 
diet, reduced the diastolic blood pressure in healthy, normotensive subjects. 
A few researchers have studied the effects of PUFA on insulin sensitivity in type 
2 diabetic subjects. For example, Kabir et al. (2007) studied the effect of 3 g/day of 
either fish oil (containing 1.8 g/day of n-3 PUFA) or a placebo (paraffin oil) using a 
double-blind two-month design in type 2 diabetic women. They found that the fish oil did 
not alter insulin sensitivity or plasma glucose, nor did it affect body weight. However, 
women in the active treatment group experienced a loss of adiposity, with a reduction in 
both abdominal (subcutaneous) fat mass as determined by computed tomography and 
adipocyte diameter (via a fat biopsy). In contrast, Mostad et al. (2006) studied two 
groups of normotriglyceridemic type 2 diabetics (men and women) who received either 
17.6 mL fish oil (5.9 total g/day of n-3 PUFA as treatment) or 17.8 mL/d of corn oil (8.5 
g/day 18:2 n-6 as control). The treatment group who received higher amounts of n-3 
PUFAs experienced a moderate increase in blood glucose and decrease in insulin 
sensitivity. Taken together, these studies suggest that a modest or high intake of PUFA 
consumed as fish oil does not improve insulin sensitivity, but may possibly play a role in 
reducing adipocyte size and/or abdominal fat mass. Collectively, these results 
demonstrate the complexity of dietary fatty acid intake on atherosclerotic CVD risk. 
Protein 
 Adequate dietary protein is required for normal growth and development. The 
Recommended Dietary Allowance (RDA) for adults is 0.8 g protein/kg of body mass 
(Food and Nutrition Board 2002). In Western cultures, it is currently estimated that 
dietary protein intake has increased in the past 50 years and exceeds the RDA by about 
80% (Franz 2002), in part due to increased portion sizes and the popularity of high 
protein diets. High protein diets (e.g., Atkins) prompted researchers to study the effect of 
high protein (> 25% of dietary energy) diets on body composition and health. These 
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diets were (and still are) popular because individuals experience (at least initially) a large 
amount of weight loss. In a review by Halton & Hu (2004), it was demonstrated that 
increased dietary protein resulted in greater loss of body weight during the long-term 
(months or years), but not in the short-term. Further, they found consistent evidence that 
higher protein diets increased satiety. According to Baba et al. (1999), a high dietary 
protein diet (45% protein, 25% carbohydrate, 30% fat) allowed obese hyperinsulinemic 
individuals to lose a greater amount of weight than those on a high carbohydrate diet 
(12% protein, 58% carbohydrate, 30% fat). What is unclear is whether high protein diets 
reduce body weight by decreasing energy intake through satiety signals (e.g., ghrelin, 
cholecystokinin, or glucagon-like peptide), increasing energy expenditure, and/or 
increasing fluid loss that is reflected early on during the weight loss regimen (Blom et al. 
2006). It has been found that a high protein intake suppressed circulating ghrelin, 
whereas it elevated cholecystokinin and glucagon-like peptide-1 in 72 healthy men in a 
randomized, crossover study of four preloads containing protein (soy, whey, gluten) or 
glucose (Bowen et al. 2006). Increased energy expenditure may be due to the higher 
thermic effect of protein as compared to carbohydrate or fat and/or upregulation of 
uncoupling proteins and facilitative thermogenesis (Halton & Hu 2004). Further, dietary 
protein is thought to be involved in the pathogenesis of insulin resistance by modulating 
glucose and energy homeostasis (Tremblay et al. 2007). Dietary protein may not only 
affect body composition, but also insulin secretion and action, thereby playing a role in 
regulating glucose. According to Linn et al. (2000), consumption of a moderately high 
protein diet (1.25-2.41 g/day) versus a low protein diet (0.57-0.80 g/day) for six months 
in healthy nonobese subjects, induced a higher-glucose stimulated insulin secretion, 
increased fasting glucose concentration, impaired suppression of hepatic glucose output 
by insulin, and enhanced gluconeogenesis. 
Appetitive Hormones 
In the past, adipose tissue has been thought of merely as a storage depot for fat. 
However, adipose tissue more recently has been examined as a metabolically active 
tissue playing a role in food intake regulation. Adipose tissue releases more than 20 
substances into circulation (Guerre-Millo 2004) making it the largest endocrine organ. 
Adipose tissue releases cytokines, termed adipocytokines, such as tumor necrosis 
factor-alpha, adipsin, interleukin-6, resistin, adiponectin, leptin, angiotensinogen, and 
plasminogen activator inhibitor-1. The amount and frequency of food consumed is 
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mediated in part by the adipocytokines, adiponectin and leptin, the most intensively 
studied hormones released from adipose tissue. Further, hormones produced by the 
stomach and pancreas, ghrelin and insulin, respectively, play a significant role in energy 
homeostasis. Evidence suggests that dysregulation of adipocytokine production 
promotes the development of the metabolic and vascular diseases related to obesity 
(Funahashi et al. 1999). These hormones and their interactions are complex, but each 
plays a specific role in regulating energy homeostasis, as summarized in the following 
sections. 
Adiponectin 
 The most abundant serum adipocytokine, adiponectin (also referred to as 
AdipoQ, ACRP30, apM1), was discovered in the mid 1990s by four different research 
groups (Scherer et al. 1995; Hu et al. 1996; Maeda et al. 1996; Nakano et al. 1996). This 
30 kDa hormone is produced exclusively by mature adipocytes in visceral, 
subcutaneous, and bone marrow fat depots (Weyer et al. 2001). It has been reported 
that visceral adipose tissue produces the greater proportion of adiponectin on a gram-
for-gram basis when compared with subcutaneous adipose tissue (Motoshima et al. 
2002). Adiponectin is related to the complement C1q family containing a carboxyl-
terminal globular domain and an amino-terminal collagenous domain (Scherer et al. 
1995). Research from both animal and human studies have provided evidence that 
adiponectin increases insulin sensitivity (Yamauchi et al. 2002), exerts anti-atherogenic 
(Ouchi et al. 2001) and anti-inflammatory properties (Yokota et al. 2000), and may 
improve the lipoprotein profile (Rothenbacher et al. 2005). Fruebis et al. (2001) were the 
first researchers to provide evidence that adiponectin regulated lipid metabolism and 
body composition. Exogenous administration of adiponectin to mice caused a decrease 
in circulating concentrations of glucose, free fatty acids, and TAG (Fruebis et al. 2001; 
Yamauchi et al. 2001). Further, adiponectin decreased free fatty acids by promoting 
skeletal muscle fatty acid oxidation rather than storage by activating 5’AMP-activated 
protein kinase. This in turn activated a cascade that increased fatty acid transport into 
the mitochondria and hence stimulated fatty acid oxidation (Yamauchi et al. 2002; Jacobi 
et al. 2006). Activated AMP-kinase increased acetyl coenzyme A carboxylase 
phosphorylation, reduced malonyl coenzyme A production, increased carnitine palmitoyl 
transferase-1 activity, and thus increased mitochondrial fatty acid oxidation (Chen et al. 
2005). Further, Kubota et al. (2007) recently found that adiponectin enhanced AMP-
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kinase activity in the arcuate hypothalamus via an adiponectin receptor, to not only 
stimulate food intake in mice, but decrease energy expenditure. 
Typically, obese or insulin-resistant individuals (Weyer et al. 2001), as well as 
those with coronary artery disease (Hotta et al. 2000), have a low adiponectin 
concentration. Low expression of adiponectin in skeletal muscle with obesity and 
diabetes in both humans (Civitarese et al. 2004) and rodents (Tsuchida et al. 2004) has 
been suggested to contribute to suppressed rates of fatty acid oxidation. In fact, Chen et 
al. (2005) studied cultured primary myotubes derived from skeletal muscle of lean, 
obese, and obese type 2 diabetic subjects and reported that in lean subjects, globular 
adiponectin stimulated skeletal muscle AMP-kinase, acetyl coenzyme A carboxylase 
phosphorylation, and fatty acid oxidation. In contrast, obese subjects had a low 
concentration of adiponectin, thereby blunting AMP-kinase signals to the myotubes. 
Obese type 2 diabetic subjects had an adiponectin concentration that ablated acetyl 
coenzyme A carboxylase phosphorylation and fatty acid oxidation. A study by Berg et al. 
(2001) suggested that adiponectin was a potent insulin enhancer by decreasing hepatic 
gluconeogenesis and muscle TAG concentration, suggesting that adiponectin sends 
signals from adipose tissue to the muscle and liver. 
Adiponectin is increased with weight loss (Faraj et al. 2003) and individuals with 
high adiponectin are less likely to develop type 2 diabetes, whereas those with low 
adiponectin are more likely to develop this disease (Spranger et al. 2003). In this 
prospective study of apparently healthy adults aged 35-65, women had a higher mean 
concentration of adiponectin than men. In another study (Lindsay et al. 2002), low 
baseline adiponectin predicted the development of subsequent diabetes in humans. 
Adiponectin has been inversely associated with BMI (Hotta et al. 2000), central fat mass 
and overall body fat (Gavrila et al. 2003). In the face of adiponectin deficiency 
(hypoadiponectinemia), excess adipose tissue accumulates. Jurimae & Jurimae (2007) 
found that age, fasting insulin resistance index1, and leptin were independent 
contributors to adiponectin in middle-aged premenopausal, middle-aged 
postmenopausal, and older postmenopausal women (N=153). The adiponectin 
concentration of postmenopausal middle-aged and older women was significantly higher 
when compared with premenopausal middle-aged women. The researchers suggested 
this finding was probably due to the body composition changes as a result of 
                                                 
1 Fasting insulin resistance index = [fasting glucose (mmol/L) X fasting insulin (μIU/ml) / 25] 
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menopause. As expected, the premenopausal women were leaner and had less fat than 
the postmenopausal women. 
Leptin 
 In 1973 Coleman conducted rodent parabiosis studies on genetically obese 
ob/ob and db/db mice that provided evidence of a circulating factor that effected food 
intake (Coleman 1973). It appeared that the ob/ob mice failed to produce this factor to 
inhibit food intake whereas, the db/db mice produced this factor but did not respond with 
decreased food intake. This led to the discovery of leptin in 1994, a 16 kDa peptide of 
the ob gene (Halaas et al. 1995). Leptin is produced mainly from subcutaneous adipose 
tissue (Faraj et al. 2003). This hormone attracted much attention as a possible 
therapeutic agent for obesity. Similar to adiponectin, leptin is secreted from adipose 
tissue, but its production is proportional to fat mass, especially the amount of 
subcutaneous fat, and also has an insulin-sensitizing effect by favoring tissue fatty-acid 
oxidation through activation of AMP-kinase (Guerre-Millo 2004). Leptin concentration is 
highly related to BMI (Lonnqvist et al. 1995; Considine et al. 1996) and leptin acts as a 
positive signal from energy reserves in adipose tissue to the brain. Leptin is transported 
into the brain via a saturable process (Banks et al. 1996). During an obese state, leptin 
concentration is elevated in most individuals (Matsubara et al. 2002; Rosicka et al. 
2003). This observation lead to the speculation that elevated leptin caused obesity and 
later that obesity may be due to leptin resistance (Caro et al. 1996). Leptin resistance 
might result from either inadequate leptin production, lack of leptin receptors, or to 
insensitivity of the leptin receptors in the brain, all of which may contribute to obesity. 
However, during obesity, leptin production is elevated and thus leptin resistance is most 
likely due to insensitivity of brain leptin receptors rather than inadequate leptin 
production (Munzberg & Myers 2005). 
The absence of leptin in the ob/ob mouse leads to massive obesity, but 
administration of leptin reduced food intake and increased energy expenditure (Halaas 
et al. 1995; Pelleymounter et al. 1995). Similarly, this result has been shown in leptin 
deficient humans who are massively obese. Leptin administration to massively obese 
individuals has been shown to result in decreased food intake and mobilization of body 
fat such that body weight is normalized (Benoit et al. 2004). In a study of Pima Indians, 
those prone to a large weight gain had a lower leptin concentration than those who had 
never been obese (Ravussin et al. 1997). A low concentration of leptin is associated with 
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a decreased rate of fat oxidation (Filozof et al. 2000). Otero et al. (2005) also has shown 
that leptin suppressed appetite, increased energy expenditure, and decreased metabolic 
efficiency. 
Insulin 
Insulin has long been known as a key peripheral regulator of food intake and 
adiposity. There are two primary actions of insulin:  homeostatic and anabolic. Insulin 
concentration is low in a fasted state in which the homeostatic role dominates, whereas 
insulin is stimulated after a meal in which the anabolic role dominates, particularly when 
carbohydrate is consumed, or with glucose infusion (Czech 1984). The beta cells of the 
pancreas synthesize insulin in response to local glucose, but also respond to amino 
acids (particularly arginine and leucine), oral hyperglycemic agents, calcium influx, 
gastric inhibitory peptide, and the parasympathetic nervous system. Insulin secretion is 
inhibited by hypoglycemia and the autonomic nervous system. Insulin signals cells to 
take up circulating glucose by signaling glucose transporters (particularly GLUT-4 
receptors) to translocate to the cell membrane (Barnard & Youngren 1992). Ultimately, 
insulin regulates glucose utilization (homeostatic role) and/or storage (anabolic role) and 
also lipid utilization (homeostatic role) and storage (anabolic role). The insulin response 
to glucose only lasts as long as glucose is elevated postprandially; insulin is then rapidly 
cleared from the blood. Without sufficient insulin, as is the case in type 1 diabetes, cells 
are unable to take up glucose, causing a hyperglycemic condition. At the same time, 
adipocytes are unable to take up lipid for storage (Cryer & Polonsky 1998). 
Plasma insulin concentration is directly related to adiposity (Woods et al. 1998), 
particularly visceral fat. Obese individuals have a higher concentration of insulin and 
secrete more insulin in response to a meal than do lean individuals (Bagdade et al. 
1967). Further, obese individuals can become insulin resistant or develop type 2 
diabetes when the insulin concentration is elevated over time. Individuals are considered 
insulin resistant when cells experience decreased sensitivity and/or responsiveness to 
the metabolic actions of insulin (Benoit et al. 2004). During an obese state, excess 
insulin is secreted to regulate the high concentration of circulating glucose. Excess 
insulin causes increased accumulation of fat in adipocytes and thus obesity is closely 
associated with type 2 diabetes. Evans et al. (1984) found that in healthy, 
premenopausal women, as WHR increased, plasma insulin concentration increased. 
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Further, obese women with androidal obesity have been found to have impaired glucose 
tolerance, as well as hyperinsulinemia (Kissebah et al. 1982). 
Insulin receptors are not only located on the membrane of cells, but also in the 
brain, specifically in the regions of the central nervous system involved in the regulation 
of food intake and body weight (Woods et al. 2003). In fact, exogenous administration of 
insulin into the brain reduced food intake and increased energy expenditure (Air et al. 
2002a). Similar to leptin, insulin enters the brain via a saturable transport process 
(Hachiya et al. 1988). Insulin and leptin interact, providing information to the brain not 
only about the size of fat mass, but also about adipose tissue distribution and important 
recent changes in metabolic status (Benoit et al. 2004). While leptin is a long-term (days) 
adiposity signal, insulin secretion assesses changes in energy storage within minutes 
and hours. 
Ghrelin 
An orexigenic peptide, ghrelin, discovered in 1999 by Kojima et al. (1999), is a 
hormone that has two independent physiologic roles. Ghrelin stimulates appetite and the 
release of growth hormone from the pituitary gland. Ghrelin, a 3.3 kDa preprohormone, 
must be proteolytically split into a 28-amino acid peptide to be activated. This peptide is 
synthesized in epithelial cells of oxyntic glands lining the fundus of the stomach, with 
smaller amounts synthesized from regions of the brain (pituitary and hypothalamus), 
kidneys, bowel, and placenta (Guan et al. 1997). Prior to the discovery of ghrelin, its 
receptor in the pituitary was characterized. The receptor located in the anterior pituitary 
is known as the growth hormone secretagogue receptor because upon stimulation, it 
secretes growth hormone. The growth hormone secretagogue receptor acts through a 
G-protein-coupled response. After gastric production, ghrelin is secreted into the 
bloodstream where it binds with receptors in the arcuate nucleus of the brain. The 
appetite-stimulating effect of ghrelin is independent of growth hormone stimulation. The 
location of ghrelin secretion in the stomach is ideal because it senses short-term 
fluctuations in energy balance, thereby stimulating meal initiation. Evidence of this was 
shown during administration of ghrelin peripherally to rodents. Ghrelin acted centrally to 
stimulate food intake (Tschop et al. 2000), increasing adiposity by decreasing fat 
oxidation. Administrating ghrelin intravenously to humans also increased adiposity and 
decreased fat utilization (Wren et al. 2001). Along with short-term regulation, ghrelin also 
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regulates body weight long-term through a complex central signaling network that 
regulates food intake and energy expenditure (Murray et al. 2003). 
There are two active forms of ghrelin commonly found in tissue and plasma:  n-
octanoyl-modified and des-acyl ghrelin. The concentration of total ghrelin (n-octanoyl-
modified plus des-acyl forms) in plasma is normally 100-150 fmol/mL. During times of 
fasting, plasma ghrelin concentrations are increased and then decreased within one 
hour after food consumption (Cummings et al. 2001), as demonstrated in the figure 
below. This study also found that the ghrelin concentration during a 24-hour period was 
reciprocal of insulin. Ghrelin rose sharply before meals while the insulin concentration 
was low; conversely, the ghrelin concentration declined post-meal, while insulin rose. 
 
Figure 4:  24-hour plasma ghrelin concentration 
 
Previous research has shown that plasma ghrelin concentration was lower in 
obese subjects than age-matched lean controls (Hansen et al. 2002), opposite than what 
one would expect. However, as obese patients lose body weight, ghrelin concentration 
increases (Cummings et al. 2002). Interestingly, in a study of obese patients receiving 
stomach-bypass surgery, the ghrelin concentration actually decreased suggesting that 
the size of the stomach may be directly related to ghrelin (Holdstock et al. 2003). In 
contrast, anorexia nervosa patients have higher plasma ghrelin, but as they gain weight, 
plasma ghrelin is decreased (Otto et al. 2001). In fact, ghrelin has been considered as a 
remedy to pathological anorexia that accompanies cancer, AIDS, tuberculosis, and 
aging by increasing food intake in these patients. A recent study by Garcia & Polvino 
(2007) studied the effects of ghrelin drug therapy (RC-1291) by providing ghrelin orally to 
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patients with cancer-associated anorexia/cachexia. These patients gained weight, 
suggesting that this may be an effective treatment for anorexia/cachexia. A ghrelin 
antagonist has been considered as a treatment for obesity by reducing the amount of 
food intake and/or reducing the sensation of hunger. To test this hypothesis, Zorrilla et 
al. (2006) used male rats and gave them a “vaccine” of ghrelin antagonist. They found 
that the immunized rats ate normally but gained less body weight and fat, suggesting 
that the rats reduced energy storage. Further testing is needed in animal models to 
ensure the safety and discover the exact mechanisms by which this “vaccine” may work. 
Inflammatory Markers 
 Obesity is considered a state of low-grade inflammation, stemming from adipose 
tissue, resulting from chronic activation of the innate immune system. Long-term 
inflammation can lead to insulin resistance that, if left untreated, can develop into 
diabetes (Bastard et al. 2006). Adipocytes secrete many proinflammatory markers (e.g., 
tumor necrosis factor-α, interleukin-6, interleukin-1β, C-reactive protein, etc.) that 
contribute to the systemic inflammatory state (Gil et al. 2007). There is mounting 
evidence that these cytokines play a large role in the development of obesity-associated 
CVD. In fact, visceral obesity is associated with increased circulating concentrations of 
C-reactive protein and interleukin-6 in obese individuals (Panagiotakos et al. 2005). 
Further, central adiposity in postmenopausal women has been shown to be related to C-
reactive protein and fibrinogen (Perry et al. 2008). Proinflammatory markers are 
increased during obesity, but also during inflammatory conditions. During an 
inflammatory condition, lymphocytes (e.g., white blood cells) migrate to the site of 
inflammation, thus acting as an acute responder to infection or inflammation. Although 
white blood cell count typically is thought of as an indicator of acute infection or 
inflammation, research has indicated that white blood cell count is also related to body 
fat in humans (Womack et al. 2007). Further research is warranted to elucidate the 
relationship between body fat and white blood cells, but it is clear that inflammation plays 
a role in obesity. 
 
OVERVIEW OF MENOPAUSE 
Definitions 
 Menopause marks the permanent end of menses and fertility (North American 
Menopause Society 2007), occurring on average by 51 years of age. According to the 
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WHO (1996), premenopause is any time in a woman’s life from puberty to her last 
menstrual period. Menopause is defined by 12 consecutive months of amenorrhea 
(North American Menopause Society 2007). Perimenopause means “around 
menopause” and is a time of irregular menstrual cycles before the final menses and lasts 
until one year after a woman’s last menses. The postmenopausal period begins at the 
time of the last menstrual period and extends through a woman’s life. The menopausal 
transition describes the time of increased menstrual cycle variability and may begin as 
early as the thirties for some women (Mitchell et al. 2000). These researchers suggest 
that during the menopausal transition, there are three key characteristics:  changes in 
cycle length and flow, irregular menses, and missed periods. The first five years after the 
last menses is considered the “early” postmenopausal period, whereas the time 
thereafter is considered the “late” postmenopausal period. Determining the exact 
occurrence of menopause is difficult because reproductive hormone concentrations and 
menopausal symptoms are exceedingly variable among women and thus have been 
deemed unsuitable markers. Further, hormone values do not necessarily relate to 
menopausal symptoms or amenorrhea (Sherman 2005), thereby forcing clinicians to use 
the one year cessation of menses as the gold standard. 
Hormonal Changes During Menopause 
 Reproductive hormones 
 During the transition through menopause, women experience physiologic and 
endocrinologic changes. With the menopausal transition, one physiologic change that 
occurs is that the menstrual cycle becomes irregular, representing a marked decrease in 
ovarian follicle number (Richardson et al. 1987) and change in hypothalamic-pituitary-
ovarian axis function (Weiss et al. 2004). Cessation of follicular development decreases 
the production of estrogen, particularly 17β-estradiol (E2), from the ovaries starting about 
one year prior to the final menstrual period (Burger et al. 1999). In addition, 
progesterone production is decreased as a woman transitions through menopause. 
Progesterone is synthesized primarily in the adrenal glands and is the hormone that 
predominates during the luteal phase of the menstrual cycle and is also the primary 
hormone that is produced in high amounts during pregnancy. The gonadotropin 
hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH), normally 
tend to increase with the occurrence of the final menstrual period (Rannevik et al. 1995), 
likely due to the decrease in estrogen. Postmenopausal concentrations of FSH and LH 
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range from 34-96 IU/L and 40-104 IU/L, respectively (Carr 1998). Estrogen provides a 
negative feedback signal to decrease LH, maintaining a low concentration of LH during 
the premenopausal period (Herbison 1998). According to Herbison (1998), estrogen also 
provides a positive feedback signal to increase LH because it induces the slight surge in 
LH concentration during ovulation. Thus, when estrogen production declines, the 
negative feedback signal is no longer present, allowing LH (and FSH) to increase. After 
the onset of menopause, there is a 10-15 fold increase in circulating FSH concentration, 
a 4-5 fold increase in LH, and more than a 90% decrease in circulating E2 (Burger 1999). 
Lastly, the androgen hormone, testosterone, has been shown to change little across the 
menopausal transition. Two studies (Rozenberg et al. 1988; Bancroft & Cawood 1996) 
have compared cross-sectionally testosterone concentration between pre- and 
postmenopausal women. They found that postmenopausal women had a lower 
concentration than the premenopausal women, but postmenopausal women have higher 
testosterone in relation to estrogen concentrations. However, according to one 
longitudinal study (Burger et al. 2000), testosterone did not change across the 
menopausal transition. Further research is needed to clarify the role of testosterone 
during menopause. 
Recently, the dimeric inhibins A and B have been described as playing a role 
during the menopausal transition. The inhibins and reproductive hormones are secreted 
from the granulosa cells lining the ovarian follicles. Thus, when follicle production begins 
to decline, there is a decrease in the concentrations of these hormones. In a longitudinal 
study of healthy women enrolled in the Melbourne Women’s Midlife Health Project 
(Burger et al. 1999), changes in inhibins A and B, as well as E2 and FSH, were 
measured in relation to the time of final menses. They found that FSH rose, whereas the 
concentrations of E2 and the inhibins fell at the time of final menses. They suggested 
that the decline in inhibins, along with E2, likely contributed to the rise of FSH. Another 
study by Burger et al. (2002) demonstrated that the earliest sign of hormonal change 
was reduced inhibin B concentration as women began the menopausal transition. 
Appetitive hormones 
Researchers have shown that appetitive hormones are related to body 
composition, but there are still many questions as to how the appetitive hormones affect 
body composition during the menopausal transition. Previous studies (Sowers et al. 
2008; Mahabir et al. 2007; Gower et al. 2000; Gavrila et al. 2003; Purnell et al. 2003; 
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Lovegrove et al. 2002) have been designed to examine the appetitive hormones in 
healthy postmenopausal women. These researchers have studied appetitive hormones 
specifically in relation to central adiposity because of the change in body composition 
that most women experience during and after menopause. Since adiponectin and leptin 
are synthesized in adipocytes, do their concentrations affect the size and distribution of 
fat cells? Alternatively, is it that menopause affects the concentration of appetitive 
hormones because of the change in reproductive hormones? It is known that the 
adipocytokines and ghrelin are related to menopause (Sowers et al. 2008), but with the 
rise in obesity, especially for postmenopausal women, it is important to understand these 
relationships and the mechanisms that might alter disease risk during the menopausal 
transition. 
Adiponectin:  Few studies have found differences in adiponectin concentration 
between pre- and postmenopausal women. Although Gavrila et al. (2003) and Jurimae & 
Jurimae (2007) found that adiponectin was significantly lower in pre- versus 
postmenopausal women, Kanaley et al. (2001) and Hong et al. (2007) did not find a 
difference in adiponectin between these two groups. They attributed the lack of 
difference in adiponectin to a lack of dramatic difference in body fat between pre- and 
postmenopausal women. The finding that adiponectin was higher in postmenopausal 
women is hard to understand because as body fat increases, adiponectin concentration 
typically decreases. Thus, one would speculate that after menopause women might 
have a lower adiponectin concentration because of their greater fat mass. Perhaps this 
might be explained by the inverse relationship between adiponectin and estrogen, 
illustrating that estrogen deficient postmenopausal women may have a higher 
adiponectin concentration than their estrogen replete premenopausal counterparts. 
Gavrila et al. (2003) found that serum E2 was a strong negative determinant of 
adiponectin in postmenopausal women; compared with premenopausal women, E2 was 
lower while adiponectin was higher in postmenopausal women. 
Leptin:  Results are inconclusive regarding leptin concentration across the 
menopausal transition. According to Kanaley et al. (2001), similar to adiponectin, leptin 
concentration was not different between pre- and early postmenopausal women. 
However, according to Rosenbaum et al. (1996), the leptin concentration in 
postmenopausal women was lower than their premenopausal counterparts. Unlike these 
studies that compared the leptin concentration in women cross-sectionally, Sowers et al. 
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(2008) measured leptin sequentially at three time points (pre-, peri-, and 
postmenopause) and found in non-obese women that the leptin concentration increased 
throughout these menopausal stages, independent of FSH concentration. They 
suggested that leptin may play a direct role in affecting reproductive hormone 
concentration during the transition. This might be due to the ability of leptin to 
communicate with the brain at the hypothalamic-pituitary-ovarian axis, possibly allowing 
it to affect reproductive hormone action (Licinio et al. 1998), or conversely, reproductive 
hormones might also affect leptin action. Regardless, it is important to further investigate 
this relationship because of the important health-related consequences of obesity that 
may accompany menopause. 
Insulin:  The transition through menopause is marked by a decrease in insulin 
secretion and a parallel decrease in hepatic insulin clearance (Walton et al. 1993), 
thereby increasing the risk of elevated blood glucose concentration and diabetes. 
Postmenopausal status and aging both increase the risk of insulin resistance, as 
indicated by the statistic that ~44% of untreated (not taking hormone therapy) 
postmenopausal women are insulin resistant (Lindheim et al. 1993). Whether this 
decrease in insulin concentration and sensitivity is related to the decline in estrogen 
production has been suggested (Van Pelt et al. 2008), but is still unclear. However, it 
has been shown that estrogen plays a role in maintaining glucose homeostasis by 
affecting insulin secretion and clearance (Godsland 2005). Hormone therapy has been 
shown to increase insulin clearance and action, thereby increasing glucose disposal in 
postmenopausal women (Van Pelt et al. 2003) and hence decreasing the risk of insulin 
resistance and diabetes. 
Ghrelin:  Research investigating the relationship between ghrelin and 
menopause is lacking and the research that is presently available is conflicting. Sowers 
et al. (2008) found that ghrelin concentration was higher in both obese and non-obese 
perimenopausal women as compared with pre- and postmenopausal women. This 
increase in ghrelin during perimenopause coincidently occurs during increased cycle 
irregularity, accompanied by wide fluctuations in the circulating reproductive hormones. 
There is question as to whether ghrelin influences the reproductive hormones and/or 
body composition and thus further investigation is warranted. 
Summary:  Each of the appetitive hormones has been studied in 
postmenopausal women, although more research to determine their role throughout the 
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menopausal transition is needed. Further, it might be that a combination of these 
hormones impact reproductive hormones and body composition, thereby influencing the 
health of postmenopausal women. For example, it has been found that adiponectin is 
inversely related to leptin, which is consistent with some (Jurimae & Jurimae 2007; 
Matsubara et al. 2002) but not all studies (Gavrila et al. 2003). Both low adiponectin and 
high leptin have been related to an increased risk of insulin resistance (Matsubara et al. 
2002). Hong et al. (2007) found that in obese postmenopausal women, an increase in 
leptin contributed to insulin resistance. Further investigation is certainly warranted. 
Long-Term Health Consequences of Menopause 
 Increased risk of obesity:  Change in overall and regional adiposity 
Menopause-induced hormonal changes result in an increase in overall adiposity 
(Tchernof et al. 2004), but especially visceral adiposity (Lovejoy et al. 2008). This 
indicates that the change in reproductive hormone concentration during menopause may 
be linked to the change in body composition (Sowers et al. 2007). Premenopausal 
women who have a normal concentration of estrogen have a greater tendency to store 
fat in the gluteo-femoral (gynoidal) region; however, the loss of estrogen with 
menopause is associated with an increase in centrally-located (androidal region) fat. 
This is accompanied by an increase in disease risk, specifically the risk of insulin 
resistance (Lee et al. 2004), atherosclerotic CVD (Carr 2003), dyslipidemia (Schnatz & 
Schnatz 2006), hypertension (Reckelhoff & Fortepiani 2004), and breast cancer (Sellers 
et al. 1992). Although the mechanism responsible for the increase in central adiposity is 
unclear, the evidence presently available indicates that menopause is associated with a 
change in metabolic activity of the adipose tissue. Ferrara et al. (2002) has reported that 
adipose tissue lipoprotein lipase, a key enzyme in lipid metabolism, storage, and 
distribution, was significantly more active in gluteal and abdominal adipocytes from 
postmenopausal compared with perimenopausal women. This suggests that the 
adipocytes in the gluteal and abdominal area in postmenopausal women are more likely 
to store and distribute fat than in perimenopausal women, providing a possible link to the 
increased central adiposity that most postmenopausal women experience. Additionally, 
Lovejoy et al. (2008) performed a longitudinal study following 158 healthy 
premenopausal women for four years and suggested that the increase in central fat 
mass was related to fat oxidation and energy expenditure. They found that 24-hour fat 
oxidation declined in women who transitioned from pre- to postmenopause and 
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suggested that this may predispose postmenopausal women to gain body fat, 
particularly in the central region. They also found that energy expenditure (assessed by 
an activity monitor) decreased in women who transitioned into menopause compared to 
women who remained premenopausal during the course of the study. Some attribute 
changes in body composition to changes in reproductive hormone status during the 
menopausal transition. The Study of Women’s Health Across the Nation (SWAN), a 
survey of ~13,000 multi-ethnic women in the U.S., indicated that in 543 pre- and 
perimenopausal Caucasian and African-American women, a change in circulating FSH 
(increase) was positively related to change in fat mass (increase) during six years of 
follow-up (Sowers et al. 2007). They concluded that ovarian aging plays a role in body 
composition changes during the menopausal transition. More research is necessary to 
study women through the menopausal transition to determine the mechanisms of the 
postmenopausal “shift” of fat from the gynoidal to the androidal region. 
 Increased risk of chronic disease 
 Postmenopausal women are at a greater risk of osteoporosis (Siris et al. 2006) 
and atherosclerotic CVD (Stangl et al. 2002), specifically coronary artery disease, than 
premenopausal women, most likely related to the loss of estrogen protection (Barrett-
Conner & Bush 1991). Along with increased body weight, many unfavorable 
consequences typically occur after menopause, including changes in lipid and 
lipoprotein metabolism (Stevenson et al. 1993), glucose and insulin metabolism (Walton 
et al. 1993), and coagulation and fibrinolysis (Winkler 1992). Stevenson et al. (1993) 
found that postmenopausal women (independent of age) had significantly higher 
circulating concentrations of total cholesterol, TAG, and LDL cholesterol, but lower HDL 
cholesterol. Additionally, pancreatic insulin secretion was markedly lower in 
postmenopausal versus premenopausal women (Walton et al. 1993). Dyslipidemia and 
insulin resistance may develop from highly lipolytic visceral adipocytes that increase 
circulating free fatty acids, which in turn interfere with hepatic clearance of insulin and 
enhance hepatic synthesis of TAG-rich lipoproteins (Tchernof et al. 2000). Taken 
together, these studies provide valuable information as to why postmenopausal women 
are at an increased risk of atherosclerotic CVD. However, the relationship between 
alterations in reproductive hormone concentrations at menopause and CVD is still 
uncertain. Many menopausal women are searching for treatment options other than 
hormones to decrease their risk of chronic diseases. 
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Treatment of Menopause 
Common hormonal therapies 
Postmenopausal women are often prescribed HT to relieve menopause-related 
symptoms, specifically vasomotor symptoms (hot flushes), memory loss, and loss of 
sleep. Additionally, many women are prescribed HT to prevent bone loss, and for many, 
HT has been shown to beneficially affect body composition by preventing an increase in 
body weight. A study with postmenopausal women found that after five years of HT, the 
postmenopausal increment of fat mass, especially in the trunk region, was attenuated by 
60% (Kristensen et al. 1999). 
There are two common types of HT available, estrogen and estrogen plus 
progesterone, with choices of route of delivery (oral, transdermal, vaginal, nasal) for 
each formulation, dependent upon individual preference. Various HT formulations are 
prescribed for different indications, but all carry contraindications in particular 
circumstances. In addition, side effects have been observed with all types of therapies, 
as illustrated and summarized by the Writing Group of the Women’s Health Initiative 
Trial (Rossouw et al. 2002). Since results of this trial have been published, physicians 
have tended to prescribe lower doses of both estrogen and progesterone to exert similar 
benefits, but with less risk of adverse effects. “Natural” hormones appear to be more 
widely accepted by women than synthetic hormones (Fournier et al. 2008), but likely 
carry similar risks. 
Estrogen:  Estrogen therapy is typically used to treat vasomotor symptoms, such 
as hot flushes and/or nights sweats. Also, estrogen therapy has been shown to help 
prevent osteoporosis (Greendale et al. 1998) in postmenopausal women who have a 
relative estrogen deficiency after menopause. Women who have undergone a 
hysterectomy are typically prescribed estrogen alone, whereas women with an intact 
uterus taking estrogen alone are at an increased risk for developing endometrial cancer 
due to over-stimulation of the endometrial tissue. This could lead to continuous glandular 
cell proliferation (Sitruk-Ware 2007), increasing the likelihood of endometrial cancer. 
Currently, both oral and non-oral (e.g. transdermal, vaginal, and nasal) estrogen 
therapies are available. There is growing evidence that non-oral estrogen is better than 
oral because non-oral estrogen avoids metabolism through the gastrointestinal tract and 
liver, known as the “first pass”. Thus, non-oral administration does not stimulate hepatic 
synthesis, and hence does not promote dyslipidemia. Also, non-oral administration of 
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estrogen allows the serum concentration to more accurately reflect the dose delivered 
and absorbed (Sitruk-Ware 2007). Vaginal delivery of estrogen can be via a silastic ring 
or cream, both of which have been shown to be effective methods for delivery of 
estrogen. Nash et al. (1999) used vaginal rings to deliver 60-140 ug E2/day for six 
months and effectively relieved menopausal symptoms in 35 women who had 
undergone a hysterectomy. Additionally, nasal administration of HT (300 ug/day of E2) 
has been shown to be an effective method to reduce menopausal symptoms for 
postmenopausal women. (Studd et al. 1999). This method was (and is) well tolerated 
and accepted by women. 
Estrogen plus progesterone:  Combined HT, estrogen plus progesterone (or 
synthetic progestin), is a commonly used formulation. This type of therapy is 
recommended for women with an intact uterus because estrogen alone stimulates the 
endometrium, whereas the addition of progesterone exerts a protective effect on the 
endometrium. However, the estrogen-progesterone preparations have been challenged 
because they are thought to impact other target tissues, such as breast cells (Beral 
2003). Progesterone therapy may be delivered vaginally via a gel or ring, or via an 
intrauterine device, although transdermal gels or patches are also available. Both oral 
and non-oral estrogen plus progesterone are available, whereas non-oral delivery avoids 
the first pass effect, thereby limiting systemic action.  
Alternative therapy:  Soy isoflavones 
 In 2002, the Women’s Health Initiative Trial demonstrated that HT may carry 
greater risks than benefits (Rossouw et al. 2002). Some of these risks include breast 
and uterine cancer, stroke, and thromboembolic disease. Since these studies became 
available, HT use has declined (Ettinger et al. 2003) and women are searching for 
alternative therapies to relieve menopausal symptoms. Further, the rising health 
concerns that surround central adiposity after menopause have driven women to search 
for ways to either maintain or lose weight. Finding effective therapies to ameliorate the 
rising prevalence of obesity among postmenopausal women is crucial. Globally, some of 
the lowest disease rates are in Asia where soy food consumption is high. A typical Asian 
diet contains about 20-80 mg isoflavones/day (Somekawa et al. 2001). The low disease 
rates among Asians have led health professionals to question whether soy foods 
(containing isoflavones) might affect body composition. Further, the risks of HT outweigh 
the benefits for some women and thus many are interested in a more “natural” approach. 
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Soy isoflavones, with their estrogen-like properties, are thought by some to be an ideal 
alternative to HT because of perceived health benefits (Messina 2002). However, we 
have sparse information on the effect of soy isoflavones on body composition in 
humans. 
 Food sources, health benefits:  Soy isoflavones have been touted as a natural 
and safe alternative to HT, in part because Asian women report fewer menopausal 
symptoms (Boulet et al. 1994) and they have lower rates of obesity (Stevens & Nowicki 
2003). Soy isoflavones are thought to relieve menopausal symptoms (Upmalis et al. 
2000), similar to estrogen, but further research is needed to understand the underlying 
mechanisms. Isoflavones are found naturally in soybeans and products made from 
soybeans, as well as red clover. Soybeans provide both soy protein and soy isoflavones. 
Soy protein is thought to exert a number of health benefits and, in fact, the Food and 
Drug Administration in 1999 issued a health claim stating that 25 grams of soy 
protein/day may reduce the risk of coronary heart disease (Food and Drug 
Administration 1999). However, this amount may be too high for most consumers to 
achieve and they did not provide a recommendation about soy isoflavone intake. 
Messina (2002) recommended 15 grams of soy protein and 50 mg of isoflavones per 
day for a healthy adult population, which may exert hypocholesterolemic effects while 
providing protection from diseases, such as CVD, cancer, and osteoporosis. A diet rich 
in soy isoflavones has been shown to decrease the risk of breast cancer (Linseisen et al. 
2004), prostate cancer (Ozasa et al. 2004), and CVD (Tikkanen et al. 1998), as well as 
reduce bone loss (Alekel et al. 2000). Soy isoflavone metabolites have also been shown 
to exert potent antioxidant effects (Arora et al. 1998). Goodman-Gruen and Kritz-
Silverstein (2001) found that mean BMI and waist circumference were significantly 
smaller in postmenopausal women who reported consuming ≥1.0 mg/day of isoflavone 
genistein compared with women who did not consume any isoflavones. However, this 
cross-sectional study was limited by inadequate measures of body composition, self-
reported food intake, small amount of isoflavone intake, and failure to account for dietary 
intake (other than energy) or physical activity that might have influenced the results. 
Structure, metabolism:  Isoflavones (Figure 5) are composed primarily of the β-
glycoside forms genistin, daidzin, glycitin, and the aglycone forms genistein, daidzein, 
and glycitein. Although isoflavones are primarily in the glycosidic form in foods, this form 
has not been detected in plasma or urine; thus, it is thought that the isoflavones are 
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metabolized by glucosidases prior to absorption, converting the isoflavones to a more 
bioavailable form (Hendrich & Murphy 2007). The aglycone form of isoflavones typically 
diffuses across the intestinal brush border, making their absorption more rapid than the 
glycosidic forms. A greater percentage of ingested daidzein is excreted in urine than 
genistein (Bloeden et al. 2002), suggesting that daidzein is more bioavailable than 
genistein. Isoflavones are affected by many factors that impact bioavailability, such as 
solubility, absorption mechanisms, metabolism, microbial biotransformation, and 
interaction with other dietary compounds (Hendrich & Murphy 2007). 
Urinary excretion of isoflavone metabolites is highly variable because of inter-
individual variation, thus making it difficult to detect consistent trends in absorption. One 
trend has been shown to be consistent:  those individuals who are considered “high 
excreters” of urinary isoflavones also have greater fecal excretion of isoflavones (Xu et 
al. 1995). Because plasma concentrations are much lower than in urine, plasma 
concentrations are more difficult to detect. The isoflavones are readily hydrolyzed by 
intestinal bacteria (Setchell et al. 1984), perhaps accounting for the variability of 
isoflavone excretion. The microbial biotransformation of daidzein forms equol (Atkinson 
et al. 2005), which is of interest because humans who produce equol may derive greater 
benefit from soy foods. About one-third to one-half of human subjects produce equol 
(Hendrich & Murphy 2007). Case-control studies have shown that those who produce 
equol are also at a reduced risk for cancer. 
Isoflavones may be especially of interest to women because their structure is 
similar to E2 (Figure 6) (Kuiper et al. 1998). Isoflavones from plant sources can bind to 
human estrogen receptors, ERβ and ERα, and are thus called phytoestrogens. The 
structure of daidzein is most similar to the endogenous hormone E2. Isoflavones are also 
considered selective estrogen receptor modulators (SERMs) because of their ability to 
induce both estrogen agonistic and antagonistic effects (Bhathena & Velasquez 2002). 
Typically, genistein binds more strongly to ERβ, although both genistein and daidzein 
have a lesser affinity to the receptors than estrogen. ERβ receptors are widely 
distributed in tissues, and because soy isoflavones act as weak estrogens, it is important 
to understand the underlying mechanism of this relationship. Because many 
postmenopausal women are seeking alternative therapies to HT, further investigation is 
warranted. 
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Figure 5:  Isoflavone structure 
Isoflavone R1  R2  R3 
Daidzein H  H  OH 
Genistein H  OH  OH 
Glycitein OCH3  H  OH 
 
 
Figure 6:  17β-Estradiol (E2) 
 
Effects on regional fat and lean tissue distribution:  Few human epidemiologic 
studies have investigated the relationship between soy isoflavones and regional fat and 
lean tissue distribution. Animal studies suggest that overall adipose tissue is affected by 
isoflavones, but much less is known about changes in regional adipose tissue. In 2003, it 
was discovered by Naaz et al. (2003) that genistein injections into ovariectomized mice 
decreased overall adipose tissue. Arjmandi and colleagues (1996) reported that an 
isoflavone-rich soy protein diet suppressed weight gain, specifically abdominal fat 
deposition, in ovariectomized (i.e., estrogen-deficient) rats. Interestingly, Hanson et al. 
(1999) found that male hamsters fed a casein diet supplemented with the single 
isoflavone daidzein were significantly leaner and lighter at the end of a 10-week feeding 
period compared with male hamsters fed a soy protein diet containing a mixture of 
isoflavones. Further, Wagner et al. (1997) found that ovariectomized monkeys fed 
  
41
isoflavone-rich soy protein tended to have less total body mass, abdominal fat mass, 
and a lower subscapular-to-triceps skinfold thickness ratio compared with monkeys fed 
casein. Few studies, especially long-term, have been conducted in humans, specifically 
postmenopausal women, examining this relationship. Wu et al. (2006) found that one 
year of isoflavone intake significantly reduced fat mass in the trunk region in Japanese 
women. However, this study did not control for soy consumption outside of the study 
protocol, making conclusions difficult. Finally, data from the Alekel laboratory (Moeller et 
al., 2003) showed that perimenopausal women who consumed isoflavone-rich (80 
mg/day) soy protein for six months had slightly but significantly lower thigh fat mass and 
greater hip lean mass compared with women who consumed either isoflavone-poor (4.4 
mg/day) soy protein or whey protein powder. Thus, limited evidence derived primarily 
from animal studies suggests that isoflavones may favorably alter body composition. 
Although few data are available from human studies, results are intriguing. Hence, a 
well-designed, long-term prospective clinical trail is necessary to determine whether 
isoflavones have a physiologically important impact on body composition in humans. 
Although soy isoflavones, as a natural alternative to HT, may play a role in preventing fat 
mass deposition, we must further elucidate the mechanisms that may lead to changes in 
body composition. 
Effects on appetitive hormones:  Currently there is limited research studying the 
effects of soy isoflavones on appetitive hormones:  adiponectin, leptin, insulin, and 
ghrelin. Many studies have been conducted using soy protein, which contains soy 
isoflavones, but the use of soy protein makes it impossible to determine which soy 
protein-related factors may be causing the effects. Further, most studies do not isolate 
one isoflavone, thereby making it impossible to differentiate the effects due to genistein, 
daidzein, and/or glycitein. 
 Research on the effect of soy isoflavone consumption on adiponectin is very 
limited, whereas a small study (Phipps et al. 2001) reported the effect of isoflavones on 
leptin. Researchers hypothesized that a high soy isoflavone (either 65 or 130 mg/day) 
intake would result in a higher leptin concentration in postmenopausal women, possibly 
by directly signaling adipocytes to produce leptin. However, they found that isoflavones 
had no effect on leptin concentration in either pre- or postmenopausal women and 
concluded that soy isoflavones did not directly act on adipocytes to increase leptin 
production, although they did not directly measure isoflavone action on adipocytes. 
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Further, Goodman-Gruen & Kritz-Silverstein (2001) reported that consumption of 
isoflavones reduced fasting insulin concentrations in postmenopausal women. In fact, 
Jayagopal et al. (2002) demonstrated that, in response to 30 g of isolated soy protein 
with 132 mg of isoflavones per day for 12 weeks, postmenopausal women with type 2 
diabetes experienced an 8% decrease in fasting insulin and a 6.5% reduction in insulin 
resistance. Further, dietary supplementation with soy isoflavones also favorably altered 
serum lipoproteins, thereby improving their CVD risk profile. More recently, Crisafulli et 
al. (2005) observed that genistein (54 mg/day) provided to 60 healthy postmenopausal 
women resulted in lower fasting serum glucose, insulin, and HOMA-IR compared to the 
placebo. Lastly, Weickert et al. (2006) found that soy isoflavone treatment did not affect 
ghrelin concentration in 34 healthy postmenopausal women. 
 In conclusion, we have a paucity of data on the effect of isoflavones on the 
appetitive hormones. Further studies need to be conducted to determine whether soy 
isoflavones affect the appetitive hormones either directly or indirectly, and to determine 
whether this purported effect will beneficially influence body composition in 
postmenopausal women. It may be that the reproductive hormones play a role in 
regulating body composition by affecting the appetitive hormones, although the data to 
date do not allow these conclusions. 
 
SUMMARY 
 In summary, obesity is a major public health concern because of the increased 
risk of mortality from chronic disease. The location of body fat is critical in terms of 
chronic disease risk, with central adiposity conferring greater health consequences. In 
the past, adipose tissue has been thought of merely as a storage depot for fat. However, 
more recently adipose tissue has been appreciated as a metabolically active tissue 
playing a role in food intake regulation. The amount and frequency of food consumed is 
mediated in part by the adipocytokines, adiponectin and leptin. Insulin and ghrelin each 
play a role in appetite regulation, with insulin working in concert with short-term signals 
and leptin to limit food intake. Evidence suggests that dysregulation of the appetitive 
hormones promotes the development of the metabolic and CVD related to obesity. 
 During the transition through menopause, women experience cessation of 
follicular development that decreases the production of estrogen, particularly 17β-
estradiol. The loss of estrogen with menopause is associated with an increase in overall 
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and central adiposity. This is accompanied by an increase in disease risk, specifically 
the risk of insulin resistance, atherosclerotic CVD, dyslipidemia, hypertension, and 
breast cancer. The rising health concerns that surround HT and central adiposity after 
menopause have driven women to search for ways to either maintain or lose weight and 
decrease their risk of chronic disease. Soy isoflavones, with their estrogen-like 
properties, are thought by some to be an ideal alternative to HT because of perceived 
health benefits. However, we have sparse information on the effect of soy isoflavones on 
body composition in humans, especially related to the appetitive hormones. Further 
studies need to be conducted to determine whether soy isoflavones affect the appetitive 
hormones either directly or indirectly, and to determine whether this purported effect will 
beneficially influence body composition in postmenopausal women. 
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ABSTRACT 
Objective:  Body composition and energy homeostasis are thought to affect the 
appetitive hormones:  adiponectin, leptin, insulin, and ghrelin. This study examined 
whether centrally-located fat and/or overall adiposity were related to these appetitive 
hormones in healthy postmenopausal women. 
Design:  Overall and regional body composition was assessed by dual-energy X-ray 
absorptiometry in relation to plasma adiponectin, serum leptin, serum insulin, and 
plasma ghrelin in 242 postmenopausal women. 
Results:  Regression analyses revealed that the androidal-to-gynoidal fat mass ratio 
(18.0%), age (3.2%), and white blood cell count (1.8%) accounted for 28% of the 
variability in adiponectin (F=22.2; P<0.0001); androidal (waist + hip) fat mass (66.0%), 
(androidal fat mass)2 (6.2%), whole body lean mass (2.2%), and age (0.8%) accounted 
for 69% of the variability in leptin (F=102.5; P<0.0001). Regression analyses revealed 
that sagittal abdominal diameter (8.4%), glucose (5.4%), white blood cell count (2.6%), 
and dietary omega-3 fatty acids (2.0%) accounted for 32% of the variability in insulin 
(F=20.8; P<0.0001); waist circumference (12.7%), hip lean mass (2.0%), and white 
blood cell count (1.9%) accounted for 26% of the variability in ghrelin (F=20.7; 
P<0.0001). Our results indicated that centralized fat mass was the primary contributor to 
these appetitive hormones in healthy postmenopausal women. 
Conclusion:  Since central adiposity in postmenopausal women was related to 
appetitive hormones, minimizing weight gain during the menopausal transition may 
optimize appetitive hormones, thereby facilitating appetite control and weight 
maintenance. 
 
Keywords:  Adiponectin, leptin, ghrelin, androidal fat mass, postmenopausal women 
 
INTRODUCTION 
Body composition changes become evident as women transition through 
menopause. These changes include an increase in overall (total body) and central 
adiposity (androidal region), especially visceral adipose tissue (1), and a decrease in 
total and central lean tissue mass (2). In particular, central adiposity in postmenopausal 
women is a major risk factor for developing insulin resistance (3), atherosclerotic 
cardiovascular disease (CVD; 4), dyslipidemia (5), hypertension (6), and breast cancer 
(7). 
Adipose tissue is the largest endocrine organ, releasing more than 20 
substances into circulation that are termed adipocytokines (also known as adipokines), 
such as adiponectin and leptin. Adiponectin is produced exclusively by mature 
adipocytes in visceral, subcutaneous, and bone marrow fat depots (8), whereas leptin is 
produced mainly in subcutaneous adipose tissue (9). Typically, obese or insulin-resistant 
individuals (8), as well as those with coronary artery disease (10), have low adiponectin 
but elevated leptin concentrations (11). Adiponectin increases insulin sensitivity (12), 
exerts anti-inflammatory properties (13), and may improve the lipoprotein profile (14). 
Leptin signals the brain to suppress appetite, increase energy expenditure, and 
decrease metabolic efficiency (15). Further, ghrelin and insulin, produced by the 
stomach and pancreas, respectively, play a significant role in regulating food intake and 
energy homeostasis. Obese individuals who are fasting typically have low ghrelin (16), 
whereas insulin concentration is elevated (17) in obesity. Ghrelin, an orexigenic 
hormone, rises sharply before meals while insulin is low; conversely, ghrelin declines 
after meals while insulin rises (18). Collectively, these adipocytokines, ghrelin, and 
insulin are termed appetitive hormones because they affect food intake, energy 
homeostasis, and body composition. 
Centrally-located fat can be assessed using waist circumference, waist-to-hip 
ratio, and sagittal abdominal diameter measurements, although these methods do not 
distinguish between subcutaneous and visceral fat, the metabolically active fat that is 
related to disease risk. Computed tomography is considered the gold standard in 
assessing centrally-located fat, whereas dual-energy X-ray absorptiometry (DXA) 
provides an accurate and reliable estimate of overall and regional body composition (19) 
with minimal radiation exposure. However, unlike computed tomography, DXA cannot 
differentiate between subcutaneous and visceral adipose tissue because measurements 
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are only two-dimensional. Nevertheless, soft tissue analyses of DXA scans may be used 
to estimate visceral adipose tissue (20), as well as regional lean mass (21), by dividing 
the whole body scan into subregions of interest (19). 
Appetitive hormones have been studied independently for potential mechanisms, 
but it is important to examine these hormones collectively because they interact to 
regulate energy homeostasis. The hypothesis of this study was that abdominal fat would 
be directly related to serum leptin and serum insulin, but indirectly related to plasma 
adiponectin and plasma ghrelin in healthy postmenopausal women. The specific aim of 
this study was to determine abdominal fat (waist + hip) tissue mass using DXA and 
relate abdominal fat to plasma adiponectin, serum leptin, serum insulin, and plasma 
ghrelin concentrations in 242 healthy postmenopausal women. 
 
SUBJECTS AND METHODS 
Study Design 
Healthy postmenopausal women (45.8-65.0 years of age) were enrolled as part 
of a randomized, double-blind, placebo-controlled multi-center (Iowa State University 
[ISU], Ames, IA and University of California at Davis [UC-Davis], Davis, CA) NIH-funded 
clinical trial. This ongoing parent study (Soy Isoflavones for Reducing Bone Loss; 
SIRBL) was designed to examine the effect of two doses of isoflavones extracted from 
soybeans on bone loss during three years in at-risk postmenopausal women. Eligible 
participants (non-osteoporotic, without diseases or conditions, not taking hormones or 
medications) were enrolled in the ongoing parent trial starting in 2003. This ancillary 
project is focused on overall and regional body composition using DXA in which we 
report only baseline data for 242 women. We excluded 13 women at UC-Davis from this 
analysis because they did not meet the entry criteria (11 due to a thickened 
endometrium, 1 with breast cancer, 1 without a blood sample at baseline). 
Subject Screening, Selection, and Characteristics 
For the parent SIRBL project, we recruited subjects throughout the state of Iowa 
and the Sacramento region in California primarily through direct mailing lists, stories in 
local newspapers, local/regional radio advertisements, as well as other recruiting 
avenues. We screened women who responded (N=5,255) to outreach materials initially 
via a telephone questionnaire to identify healthy women who went through a natural 
menopause (cessation of menses nine months to 10 years), were not experiencing 
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excessive vasomotor symptoms, were ≤ 65 years of age, nonsmokers, and had a body 
mass index (BMI, kg/m2) ranging from 18.5 through 29.9 (inclusive) to exclude women at 
the extremes of adiposity. We excluded vegans and high alcohol consumers (>7 
servings/week) because alcohol interferes with isoflavone metabolism. The parent 
SIRBL project established the inclusion/exclusion criteria; thus, we also excluded women 
diagnosed with chronic disease and those who had a first-degree relative with breast 
cancer. We also excluded women who chronically used medications, such as 
cholesterol-lowering or anti-hypertensive medications. Use of oral hormone or estrogen 
therapy, selective estrogen receptor modulators, or other hormones within the last 12 
months, use of estrogen or progestogen creams or calcitonin within the last six months, 
use of antibiotics within the last three months, and/or any previous use of 
bisphosphonates were grounds for exclusion. 
Women who met the initial criteria via telephone (N=677) attended a pre-baseline 
appointment to determine eligibility for additional entry criteria. We measured height and 
weight to confirm BMI status and used DXA to assess bone mineral density (BMD) to 
establish eligibility. The SIRBL project is focused on prevention rather than treatment of 
disease; thus, we excluded women with osteopenia or osteoporosis based on lumbar 
spine and/or proximal femur BMD (using >1.5 SD below the young adult mean as cut-
off), with evidence of previous or existing spinal fractures, or with a high BMD (>1.0 SD 
above the mean). Once a woman qualified based on her BMD, our phlebotomist drew 
blood for a chemistry profile. We excluded women if their fasted blood values indicated 
diabetes mellitus (fasting blood glucose ≥126 mg/dl), abnormal renal (elevated 
creatinine), liver (elevated enzymes), and/or thyroid function, or elevated lipid profile (low 
density lipoprotein-cholesterol >160 mg/dl; triacylglycerol >200 mg/dl). For this ancillary 
project, we included 242 women who met our entry criteria (Figure 1). 
The respective Institutional Review Boards (IRB) at ISU (ID# 02-199) and at UC-
Davis (ID# 200210884-2) approved our study protocol, consent form, and subject-related 
materials. Approvals for the DXA procedures were obtained from each institution’s IRB 
and State Department of Public Health in Iowa and California. We obtained informed 
consent from all women at the start of pre-baseline screening. 
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Data Collection 
Questionnaires 
At the pre-baseline visit, trained interviewers administered three questionnaires 
to ensure the health status of participants:  health and medical history (modified from 
citation 22), reproductive history (modified from citation 23), and nutrition history (22). 
Subjects were asked to cease taking herbal therapies and/or dietary supplements prior 
to baseline testing. At baseline, we assessed dietary intake using a semi-quantitative 
food frequency questionnaire from Block Dietary Data Systems (Berkeley, CA). 
Body Size and Composition Measurements 
A trained anthropometrist measured standing and sitting heights (Model S100; 
Ayrton Corp., Prior Lake, MN), weight (abco Health-o-meter; Bridgeview, IL), waist 
circumference, and sagittal abdominal diameter (Holtain-Kahn abdominal caliper; 
Crosswell, Crymych Dyfed, U.K.). Sagittal abdominal diameter was measured at the 
narrowest section between the small of the back and navel, with subjects relaxed in the 
supine position with knees bent. Body composition measurements were obtained using 
(Delphi W Hologic Inc; Waltham, MA) matching DXA instruments at each site and daily 
calibration to ensure that the instruments provided comparable results. One certified 
DXA operator at ISU and one at UC-Davis performed all DXA scans, with cross-training 
between sites to ensure comparable quality control. We standardized subject placement 
for the scans and adhered to the manufacturer recommendations. One operator 
assessed overall adiposity from the whole body DXA scans. To assess central adiposity, 
one evaluator sectioned each whole body DXA scan into waist, hip, and thigh regions 
based on bone landmarks (Figure 2) (19, 24) and these regions were analyzed using 
special software (Discovery Version 12.3:7). The waist region included the first lumbar 
through the fourth lumbar vertebrae. The hip region began below the fourth lumbar 
vertebrae and extended to the tip of the greater trochanter of the femur. Lastly, the thigh 
region extended superiorly from the greater trochanter to the approximate midpoint 
between the edge of the thigh region and lateral condyle of the femur. The lateral edge 
of each region was extended distally to encompass all tissue. This analysis provided an 
estimate of the fat and lean mass within each of these three regions. The androidal-to-
gynoidal fat mass ratio was calculated for each subject:  waist + hip fat mass / thigh fat 
mass. 
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Laboratory Measurements 
Phlebotomists collected fasted (9 hours) blood samples between 0700 h and 
0800 h. We separated serum and plasma from whole blood by centrifuging for 15 
minutes (4oC) at 1000 x g and stored aliquots at -80oC until analyses. Certified clinical 
laboratories (LabCorp; Kansas City, KS at the ISU site and the UC-Davis Medical Center 
Laboratory; Sacramento, CA at UC-Davis site) analyzed our blood samples, including a 
complete blood count (CBC) with differential, general chemistry panel, and thyroid 
screen. Adiponectin (heparnized plasma), leptin (serum), insulin (serum), and ghrelin 
(total) (EDTA-treated plasma) concentrations were determined in duplicate with 
radioimmunoassay (RIA) kits (Linco Research; St. Charles, MO) using a Cobra II series 
auto-gamma counting system (Packard Instrument Company; Meriden, CT). We used 
manufacturer-provided quality controls and in-house quality control sera/plasma for 
calculating intra- and inter-assay coefficient of variation (CV). The intra-assay and inter-
assay CVs (%) for adiponectin, leptin, insulin, and ghrelin, respectively, were 1.6 and 
1.5, 3.0 and 2.7, 2.3 and 4.0, and 3.4 and 3.1. 
Statistical Analyses 
Statistical analyses were performed using SAS (version 9.1; Cary, NC) with 
results considered statistically significant at P≤0.05. The exception was that to account 
for numerous tests of normality, we considered data to be normally distributed if 
P>0.0001. Descriptive statistics included means ± standard deviation (SD) for normally 
distributed data and medians for data that were not normally distributed, with range 
provided for each variable. Ghrelin and leptin were log-transformed prior to the 
regression analyses because the residual analysis indicated nonconstant error variance, 
thus violating model assumptions. We did not log-transform adiponectin since its 
residual plot did not indicate any violations of the linear regression model assumptions. 
Based on residual analysis, adding a quadratic term (androidal fat mass2) to the leptin 
model improved the residual plot, but adding a higher-order term to the other models 
was not beneficial. Classes of variables in modeling the outcomes of interest included 
independent variables that were biologically plausible and/or significantly related using 
Pearson correlation analysis. We used stepwise regression analyses to assess the 
combined contribution of independent variables to adiponectin, leptin, insulin, and 
ghrelin. Classes of variables in modeling each of these four outcomes included:  age or 
years since menopause, overall adiposity (whole body fat mass or weight), indices of 
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centralized fat mass (waist circumference, sagittal abdominal diameter, waist fat mass, 
hip fat mass, androidal [waist + hip] fat mass, or androidal/gynoidal fat mass ratio), 
whole body lean mass, indices of centralized lean mass (waist lean mass, hip lean 
mass, thigh lean mass, hip circumference), likelihood of concomitant infection (reflected 
in white blood cell count), physical activity, energy intake-related factors (total saturated 
fatty acids, total oleic fatty acids, total omega-3 fatty acids), and total dietary protein. 
Each model included site as an obligatory variable to account for potential study site 
differences. In modeling each outcome, we removed variables that exhibited 
multicollinearity as indicated by the variance inflation factor. The variance inflation factor 
measures the impact of collinearity among the independent variables in a regression 
model and the degree to which multicollinearity degrades the precision estimate. A value 
exceeding 10 is of concern, but in weaker regression models, a value exceeding 2.5 
may be cause for concern (25). 
 
RESULTS 
Subject Characteristics 
Two hundred and forty-two healthy, postmenopausal women were included in 
this analysis. The baseline characteristics of women are presented in Table 1. Women 
ranged from 45.9 to 65.5 years of age and from 0.8 to 10.0 years since menopause. We 
enrolled three African American (1%), one Native Hawaiian (<1%), one Native American 
(<1%), three Asians (1%), seven women of more than one race (3%), two of unknown 
race (<1%), and two who chose not to report race (<1%); the remaining women were 
Caucasian (92%). Women had a wide range (17.8-32.7) of BMI values because the UC-
Davis site enrolled nine women beyond our BMI inclusion criteria. Approximately half of 
the women had a BMI <25.0 kg/m2. Overall and regional body composition as assessed 
by DXA (Table 1) indicated wide variability in both overall and regional body fat 
measures among these women. The median values for dietary intake are listed in Table 
2, illustrating wide variability of these nutrients. Values for circulating analytes are 
presented in Table 3, demonstrating that mean or median values were within the range 
reported in the literature. 
Correlation Analyses 
Pearson correlation analysis indicated a negative association between 
adiponectin and leptin (r=-0.35, P≤0.0001) and insulin (r=-0.33, P≤0.0001), but a positive 
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association between adiponectin and ghrelin (r=0.29, P≤0.0001). As expected, we 
confirmed a positive association between leptin and insulin (r=0.44, P≤0.0001) and 
glucose (r=0.23, P=0.0004), but a negative association between leptin and ghrelin (r=-
0.34, P≤0.0001). There was a negative relationship between ghrelin and insulin (r=-0.24, 
P=0.0002) and glucose (r=-0.15, P=0.02), but a positive association between insulin and 
glucose (r=0.38, P≤0.0001). 
Regression Analyses 
We performed regression analyses to examine the independent factors 
contributing to the variability in adiponectin, leptin, insulin, and ghrelin as our primary 
outcomes (Table 4). No notable multicollinearities emerged among the independent 
variables, as indicated by the low (<2) variance inflation factors in all regression models. 
Residual analyses indicated that the model assumptions of normality of error terms and 
homogeneity of residual variance were satisfied for the final regression models. 
Geographic site was significant in the adiponectin (P=0.0024), insulin (P=0.017), and 
ghrelin (P=0.0003) models, but not for leptin (P=0.59). After variable elimination was 
completed, multiple regression analyses revealed that the androidal-to-gynoidal fat mass 
ratio (18.0%), age (3.2%), and white blood cell count (1.8%) accounted for 28% of the 
variability in adiponectin (F=22.2, P≤0.0001). Regression analyses revealed that 
androidal (waist+hip) fat mass (66.0%), (androidal fat mass)2 (6.2%), whole body lean 
mass (2.2%), and age (0.8%) accounted for 69% of the variability in leptin (F=102.5, 
P≤0.0001). Regression analyses revealed that sagittal abdominal diameter (8.4%), 
glucose (5.4%), white blood cell count (2.6%), and omega-3 fatty acids (2.0%) 
accounted for 32% of the variability in insulin (F=20.8, P≤0.0001). Regression analyses 
indicated that waist circumference (12.7%), hip lean mass (2.0%), and white blood cell 
count (1.9%) accounted for 26% of the variability in ghrelin (F=20.7, P≤0.0001). 
 
DISCUSSION 
This study is unique in that we used a regional analysis of whole body DXA 
scans to examine central fat and lean mass, rather than the standard DXA analysis to 
estimate overall fat and lean mass. Our results indicated that centralized body fat 
(androidal-to-gynoidal fat mass ratio, androidal fat mass, sagittal abdominal diameter, or 
waist circumference, respectively) was the largest contributor to each circulating 
appetitive hormone:  adiponectin, leptin, insulin, or ghrelin in healthy postmenopausal 
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women. As expected, the relationship of centralized body fat to leptin and insulin was 
positive, but negative to adiponectin and ghrelin. We confirmed previous findings (21, 
26-28) of a relationship between measures of central adiposity and adiponectin, leptin, 
and insulin in healthy postmenopausal women. However, unlike previous studies, we 
found a strong negative relationship between central adiposity (reflected by waist 
circumference) and ghrelin in these women. Recent research (29) has reported a strong 
negative relationship between waist circumference and ghrelin in younger (<30 years), 
but not in mid-life (aged 30-56 years) women. Further, in a study of 79 adult opposite-
sex twin pairs, Makovey et al. (30) found a weak relationship between abdominal fat 
mass assessed by DXA and ghrelin in women, whereas this relationship in men was 
strong. Further research is needed to understand the response of ghrelin to central 
adiposity, particularly in postmenopausal women. We also confirmed the findings of 
other studies that postmenopausal women with a higher level of adiposity have higher 
concentrations of both leptin (21, 31) and insulin (28), but a lower adiponectin 
concentration (8). 
Although lean tissue is typically not considered in central body composition 
assessment, it is important to assess because it is metabolically active. Limited data 
comparing pre- versus postmenopausal women suggest a decline in both overall and 
centralized lean tissue with menopause (2). However, few studies have examined lean 
tissue in relation to appetitive hormones. Because a higher body weight requires greater 
muscle mass for movement, a higher fat mass has been associated with higher lean 
mass, mainly localized in the legs, but with a decrease in overall lean/fat ratio (32). We 
found that leptin and ghrelin were the two appetitive hormones related to lean mass in 
the regression models, with a significant negative relationship between leptin and whole 
body lean mass and positive relationship between ghrelin and hip lean mass. However, 
we hypothesized that because of the direct relationship between overall fat and lean 
mass, leptin, ghrelin, and insulin would be directly related to lean mass in the thigh 
region, whereas adiponectin would be indirectly related. Although the Pearson 
correlation analysis indicated that leptin was positively related to whole body lean mass, 
the direction of the relationship was altered once we took other factors into account. In 
probing a possible explanation, we found that in the presence of androidal fat mass, the 
direction of the relationship between whole body lean mass and leptin may have 
changed because the simple correlation (positive) between lean mass and leptin was 
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fairly weak (r=0.14, P=0.028), whereas the correlation (positive) between androidal fat 
mass and leptin was strong (r=0.77, P≤0.0001). It seemed that androidal fat mass 
thereby exerted a dominant effect in the regression model. Similar to our findings using 
correlation analysis, Mahabir et al. (21) recently found that a higher lean mass was 
associated with a higher leptin concentration, but they did not take other factors into 
account. Their participants were older (age range 49.2-78.8 years), tended toward the 
higher end of adiposity (ranged from underweight to morbidly obese status with BMI 
range 17.7-42.5 kg/m2), and were further from menopause (up to 38 years 
postmenopausal) than the women in our study. Research is needed to examine the 
relationship between lean mass and appetitive hormones. 
Interestingly, our results suggest that white blood cell count was related to 
adiponectin, ghrelin, and insulin. White blood cell count is typically used as an indicator 
of infection or inflammation. To our knowledge, none of our women had an infection 
during baseline testing, and no women exhibited an elevated white blood cell count (>11 
x109/L). Research has indicated that white blood cell count is related to body fat in 
humans (33), suggesting that adipocytokines may be involved in the adipocyte-induced 
inflammatory response. Further, Vozarova et al. (34) found that with a high white blood 
cell count, insulin sensitivity declined in non-diabetic Pima Indians. Although we did not 
assess insulin sensitivity, our study found a positive relationship between white blood 
cell count and circulating insulin in the regression model. Collectively, these studies 
suggest that white blood cells may reflect an obesity-induced inflammatory state that is 
also mirrored by the appetitive hormones. The context of our study is important because 
the majority of these women, except for 8 women at UC-Davis whose BMI was ≥30.0, 
were not considered obese based upon BMI (ranged from 17.8 to 32.7). This suggested 
that modestly elevated (but still within normal range) white blood cell count, elevated 
insulin, and low adiponectin is an unfavorable metabolic profile in overweight 
postmenopausal women. In our study, we had two women who had adiponectin 
concentrations below the reference range (5.0-30.5 μg/mL) for healthy postmenopausal 
women (35) and six women who had a higher insulin concentration than the upper limit 
of the reference range (5.0-24.0 μU/mL; 3). However, none of our women were beyond 
the reference range for white blood cell count. 
Our study suggests that age influenced adiponectin and leptin, but not ghrelin or 
insulin, concentrations in healthy postmenopausal women. Based on the regression 
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models, we noted a positive relationship between age and adiponectin, confirming 
recently reported results (36) in similarly aged (45-62 years) subjects. In contrast, but 
similar to our findings, Ostlund et al. (31) noted an inverse relationship between age and 
leptin, attributing this finding to decreased leptin production from adipose tissue and/or 
increased leptin clearance with increasing age. As expected, fasting glucose was an 
important (positive) contributor to insulin, second to sagittal abdominal diameter. 
Interestingly, omega-3 fatty acid concentration was the only dietary factor that emerged 
as significant in any of the regression models. Lombardo et al. (37) have suggested that 
in a rat model, dietary polyunsaturated fatty acids may enhance insulin sensitivity, 
thereby improving the lipoprotein profile and decreasing CVD risk. Increased CVD risk is 
related to insulin resistance because it contributes to dyslipidemia (38). We also noted 
relationships among the appetitive hormones. Adiponectin was inversely related to 
leptin, which is consistent with some (11, 36) but not all studies (26). A low concentration 
of adiponectin but a high concentration of leptin has been related to an increased risk of 
insulin resistance (11). Likewise, we found that leptin was significantly and positively 
related to insulin in these non-diabetic healthy postmenopausal women, prior to 
emergence of disease. Further, similar to Purnell et al. (27), we confirmed that ghrelin 
was negatively associated with insulin. The associations among these appetitive 
hormones are not fully understood, but adiponectin, leptin, and ghrelin may be early 
indicators of insulin resistance in overweight but healthy postmenopausal women. 
Study site was a significant factor in the adiponectin, insulin, and ghrelin models, 
also evidenced by statistical differences (P≤0.0001) in mean values between study sites, 
possibly related to the somewhat greater (P=0.077) variability in whole body fat mass in 
the women at UC-Davis (8.05-47.77 kg) compared with those at ISU (8.43-37.01 kg). 
Our entry criteria was designed to exclude women with a BMI ≥30.0, although eight 
women at UC-Davis did not meet this criterion but had a BMI >29.9. Despite no 
difference (P=0.97) in the mean value for BMI between sites, we noted a lack of 
homogeneity of variance (P=0.0030) in BMI with respect to site, likely due to the women 
at UC-Davis whose BMI ranged from 30 to 32.7. We suspect that this wider range in 
body size and adiposity at UC-Davis likely contributed to the significant site difference in 
adiponectin, insulin, and ghrelin in these regression models. 
This study was hypothesis-generating and could not determine cause and effect 
because it was cross-sectional. In addition, the participants in this study were healthy 
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postmenopausal women, primarily of Caucasian descent. Thus, our results cannot be 
generalized to all women across ethnic groups. Since central adiposity in 
postmenopausal women was related to appetitive hormones, despite the apparent 
health of these women, minimizing weight gain during the menopausal transition may 
optimize appetitive hormones, thereby facilitating appetite control and weight 
maintenance. Additional studies are needed to determine at what level central adiposity 
should be maintained to optimally affect these appetitive hormones, thus potentially 
preventing further gain in centralized fat with menopause. 
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Table 1 
Characteristics of Subjectsa at Baseline 
 Mean ± SD Range 
Age (years) 54.6 ± 3.4 45.9 – 65.5 
Years Since Menopause 3.5 ± 2.0 0.8 – 10.0 
Body Size   
Weight (kg) 67.7 ± 9.3 43.7 – 94.5 
Height (cm) 164.7 ± 6.3 146.3 – 182.2 
BMI (kg/m2) 24.9 ± 3.1 17.8 – 32.7 
Waist circumference (cm) 77.9 ± 8.0 59.1 – 100.6 
Hip circumference (cm) 100.3 ± 6.8 80.9 – 118.2 
Waist-to-hip ratio 0.8 ± 0.1 0.6 – 0.9 
Sagittal abdominal diameter (cm) 18.6 ± 2.3 11.0 – 25.2 
Overall Body Compositionb   
Fat mass (kg) 23.26 ± 6.35 8.05 – 47.78 
Fat mass (%) 34.5 ± 5.7 18.1 – 55.9 
Lean mass (kg) 43.18 ± 4.60 29.49 – 55.59 
Regional Body Compositionb   
Waist fat (kg) 2.37 ± 1.10 0.39 – 5.59 
Waist fat (%) 28.6 ± 8.7 7.1 – 52.5 
Hip fat (kg) 3.38 ± 1.05 0.72 – 6.41 
Hip fat (%) 32.9 ± 5.9 12.1 – 51.6 
Thigh fat (kg) 5.28 ± 1.34 2.12 – 10.85 
Thigh fat (%) 38.7 ± 5.0 24.2 – 59.7 
Androidal (waist + hip) fat (kg) 5.75 ± 2.06 1.12 – 11.78 
Androidal-to-gynoidal fat mass ratio 1.09 ± 0.30 0.46 – 2.21 
Waist lean (kg) 5.53 ± 0.72 3.50 – 7.52 
Hip lean (kg) 6.71 ± 0.93 4.13 – 9.23 
Thigh lean (kg) 8.20 ± 1.04 4.85 – 11.42 
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a Number of subjects = 242 for all variables, except sagittal abdominal diameter 
(N=237) because 5 of these values were missing due to instrument 
malfunction. 
b Assessed by DXA (dual-energy x-ray absorptiometry). 
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Table 2 
Dietary Intake of Subjectsa at Baseline 
Nutrient Intake from Foodb,c Median Range 
Total Energy (kJ) 6455 1772 – 19,096 
Carbohydrate (g) 175 27 – 476 
Protein (g) 61 15 – 168 
Total Fat (g) 65 17 – 247 
Saturated Fat (g) 19 5 – 65 
Trans Saturated Fat (g) 5 0.8 – 25 
Oleic Fatty Acidd (g) 25 6 – 97 
Linoleic Fatty Acidd (g)  16 3 – 70 
Total Omega-3 Fatty Acid (g) 1.4 0.3 – 5 
Fiber (g) 16 4 – 49 
 
a The number of subjects was 242 for all variables. 
b Reported from Semi-Quantitative Food Frequency Questionnaire. 
c Distributions for these variables were not normal and thus median 
values are reported. 
d Represents monounsaturated and polyunsaturated fatty acids, 
respectively. 
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Table 3 
Circulating Analytes of Subjectsa at Baseline 
Analyte Mean ± SD Median Range Reference Range
Plasma Adiponectin (μg/mL)b  17.3 3.2 – 37.1 5.0 – 30.5d 
Serum Leptin (ng/mL)b  12.8 2.6 – 34.9 2.0 – 54.0d 
Plasma Ghrelin (pg/mL)b  938 
 
345 – 2383 
[713 – 1198]e 
995 – 1794e 
Serum Insulin (μU/mL)c 11.6 ± 5.4  0.1 – 36.1 5.0 – 24.0f 
Serum Glucose (mg/dL)c 85.5 ± 8.8  57.0 – 117.0 82.0 – 116.0f 
White Blood Cell Count 
(x109/L)a,c 
5.07 ± 1.03 
 
2.3 – 8.4 4.5 – 11.0g 
 
a Number of subjects = 242 for the adipocytokines, ghrelin, insulin, and glucose; number 
of subjects = 237 for white blood cell count. 
b Distributions were not normal; thus, median values are reported. 
c Distributions were normal; thus, mean ± SD are reported. 
d Reference range reported for healthy postmenopausal women (35). 
e Interquartile range for study participants in comparison with interquartile range reported 
for postmenopausal women (39). 
f Reference range reported for healthy postmenopausal women (3). 
g Reference range reported for adults (40). 
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Table 4 
Regression Analyses:  Contributors to Appetitive Hormones 
 
Adiponectina 
Overall Model R2=27.7% (Adj R2=26.4%)       [F=22.19; df=(4, 232)]     P≤0.0001 
Parameter 
Parameter 
Estimate 
Percentage 
Varianced 
P valuee 
Variance 
Inflation Factorf 
Intercept 16.93727  0.0026  
Study site -2.10013 2.9 0.0024 1.07 
And/Gyn Fat Mass -8.80741 18.0 ≤ 0.0001 1.10 
Age 0.31884 3.2 0.0017 1.04 
White Blood Cell Count -0.81601 1.8 0.018 1.13 
 
Leptinb,g 
Overall Model R2=68.5% (Adj R2=67.8%)       [F=102.51; df=(5, 236)]     P≤0.0001 
Parameter 
Parameter 
Estimate 
Percentage 
Varianced 
P valuee 
Variance 
Inflation Factorf 
Intercept 2.84103  ≤ 0.0001  
Study site -0.02111 0.04 0.5929 1.01 
Androidal Fat Mass 0.00023957 66.0 ≤ 0.0001 1.28 
(Androidal Fat Mass)2 -2.47059E-8 6.2 ≤ 0.0001 1.13 
Whole Body Lean Mass -0.00001834 2.2 ≤ 0.0001 1.13 
Age -0.01434 0.8 0.0147 1.03 
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Insulinc 
Overall Model R2=31.5% (Adj R2=30.0%)     [F=20.82; df=(5, 226)]     P≤0.0001 
Parameter 
Parameter 
Estimate 
Percentage 
Varianced 
P valuee 
Variance 
Inflation Factorf 
Intercept -15.70447  ≤ 0.0001  
Study site -1.50451 1.7 0.017 1.09 
Sagittal Abdominal 
Diameter 
0.71995 8.4 ≤ 0.0001 1.14 
Glucose 0.15127 5.4 ≤ 0.0001 1.14 
White Blood Cell Count 0.93610 2.6 0.0038 1.22 
Omega-3 Fatty acids -0.94795 2.0 0.011 1.05 
 
Ghrelina,g 
Overall Model R2=26.3% (Adj R2=25.0%)     [F=20.67; df=(4, 232)]     P≤0.0001 
Parameter 
Parameter 
Estimate 
Percentage 
Varianced 
P valuee 
Variance 
Inflation Factorf 
Intercept 8.64936  ≤ 0.0001  
Study site -0.17405 4.3 0.0003 1.13 
Waist Circumference -0.02269 12.7 ≤ 0.0001 1.61 
Hip Lean Mass 0.00007417 2.0 0.013 1.50 
White Blood Cell Count -0.05657 1.9 0.015 1.13 
 
a N = 237 for the adiponectin and ghrelin models because 5 women were missing CBC 
values. 
b N = 242 for the leptin model. 
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c N = 232 for the insulin model because 5 women were missing CBC values and 5 
women were missing sagittal abdominal diameter measurements. 
d Squared semi-partial Type II correlation coefficient; accounts for shared variance 
among variables. 
e Variables (except site) left in the model were significant at P ≤ 0.10 level. 
f Measures the impact of collinearity among the independent variables in a regression 
equation and the degree to which multicollinearity degrades the precision estimate. 
g Leptin and ghrelin were log transformed because they were not normally distributed. 
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Figure 1:  Subject screening and enrollment flow chart 
a We excluded 13 women at UC-Davis from this analysis because they did not meet 
entry criteria (11 due to a thickened endometrium, 1 with breast cancer, 1 without a 
baseline blood sample) 
Completed Telephone screening = 5,225
Excluded = 422 
     Did not meet inclusion criteria = 335 
     Did not want to participate = 87 
Randomized to treatment = 255 
Included in this analysis = 242a 
Completed pre-baseline screening = 677
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Figure 2:  Whole body DXA scan with regional soft tissue analysis 
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GENERAL CONCLUSIONS 
 In summary, the results from our primary objective of this ancillary study suggest 
that centralized body fat (androidal-to-gynoidal fat mass ratio, androidal fat mass, 
sagittal abdominal diameter, or waist circumference) was the largest contributor to each 
circulating appetitive hormone:  adiponectin, leptin, insulin, or ghrelin, respectively, in 
healthy postmenopausal women. As expected, the relationship of centralized body fat to 
leptin and insulin was positive, but negative to adiponectin and ghrelin. This study is 
unique in that we used a regional analysis of the whole body DXA scan to examine 
central fat and lean mass, rather than the standard DXA analysis to estimate overall fat 
and lean mass. Few studies have examined lean tissue in relation to appetitive 
hormones; however, we found that lean mass in the regression models was related to 
leptin and ghrelin, with a significant negative relationship between leptin and whole body 
lean mass and a positive relationship between ghrelin and hip lean mass. Future studies 
should further investigate how these appetitive hormones affect lean mass and what 
factors might influence these appetitive hormones to optimally affect lean mass. 
The results from our first objective revealed that the androidal-to-gynoidal fat 
mass ratio, age, and white blood cell count accounted for 28% of the variability in 
adiponectin (P<0.0001); androidal (waist + hip) fat mass, androidal fat mass2, whole 
body lean mass, and age accounted for 69% of the variability in leptin (P<0.0001). 
Regression analyses revealed that sagittal abdominal diameter, glucose, white blood cell 
count, and dietary omega-3 fatty acids accounted for 32% of the variability in insulin 
(P<0.0001); waist circumference, hip lean mass, and white blood cell count accounted 
for 26% of the variability in ghrelin (P<0.0001). Additional studies are needed to 
determine at what level central adiposity should be maintained to optimally affect these 
appetitive hormones, thus potentially preventing further gain in centralized fat with 
menopause. 
Data analyses will be conducted in the near future to fulfill the second and third 
objectives. We will determine the effect of two doses of soy isoflavones (80 and 120 
mg/day) on change in central adiposity and thigh lean mass, as mediated by circulating 
adiponectin, leptin, insulin, and ghrelin in healthy postmenopausal women. 
